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Resumo 
 
Palavras chave Ciclodextrinas, complexos de inclusão, extrato de gengibre, gingerois, óleo essencial de 
Cistus ladanifer 
 
Resumo A inclusão em ciclodextrinas (CDs) de hóspedes multi-componente, tais como óleos 
essenciais e extratos de plantas, é um tema atual e útil para uma série de aplicações nas 
indústrias alimentar, cosmética e farmacêutica. No presente trabalho foram estudados dois 
destes sistemas, tendo por hóspedes o óleo essencial de Cistus ladanifer e uma mistura 
de gingerois extraídos de rizoma fresco de gengibre.  
A composição do óleo essencial de C. ladanifer foi estudada por GC-MS, tendo-se 
identificado 94,3% dos seus componentes e determinado a massa molecular aproximada 
em 143,7 g.mol-1. O óleo foi usado para formar complexos de inclusão com as 
ciclodextrinas beta e gama. A identificação dos componentes do óleo incluídos 
preferencialmente em cada CD foi feita por extração com clorofórmio e análise por GC-MS, 
tendo-se observado inclusão preferencial de compostos de maior peso molecular na 
ciclodextrina beta, enquanto a ciclodextrina gama incluiu compostos de menor peso 
molecular. Os complexos de inclusão foram analisados no estado sólido por 
espectroscopia de infravermelho (FTIR), {1H} 13C CP-MAS RMN e difração de raios X de 
pós (PXRD), postulando-se empacotamento em canal para ambos os complexos. 
A mistura de gingerois, obtida a partir de gengibre fresco por maceração em acetona e 
purificação em coluna, foi analisada por 1H RMN e espectrometria de massa (ESI-QTOF), 
contendo 54,05 % de 6-gingerol, 19,45% de 8-gingerol e 26,5 % de 10-gingerol, a que 
corresponde uma massa molecular de 314,7 g.mol-1. O complexo γ-CD·gingerois, obtido 
por co-precipitação, foi caracterizado por FTIR, {1H} 13C CP-MAS RMN, DSC e PXRD. 
Também neste caso foi observado o empacotamento em canal. Por um ajuntamento 
segundo Pawley, foi possível refinar os parâmetros de célula em 
a = b = 23,886(3) Å e c = 23,356(3) Å (tetragonal). A atividade antioxidante de 
γ-CD·gingerois foi estudada pelo ensaio de proteção do β-caroteno, tendo-se obtido 
resultados similares aos dos gingerois não incluídos. Os gingerois e o γ-CD·gingerois 
foram usados para preparar iogurte fortificado com 1% (m/m) de gingerol (ou equivalente 
de complexo) tendo-se verificado que o complexo é mais facilmente disperso na matriz do 
que os gingerois não encapsulados. A cor do iogurte fortificado com γ-CD·gingerois 
apresentou-se mais semelhante à do iogurte simples enquanto para o iogurte com 
gingerois registaram maiores diferenças. Os iogurtes fortificados foram ainda estudados 
quanto à durabilidade, não se tendo observado alterações de pH nem aparecimento de 
odores desagradáveis durante quatro semanas, enquanto no iogurte simples a formação 
de odor se iniciou entre a segunda e a terceira semana. A atividade antioxidante dos 
iogurtes fortificados medida pelo método de ABTS foi superior à do controlo, sendo a 
condição mais promissora verificada para a amostra com gingerois. Estes resultados 
sugerem que a matriz interfere com a atividade antioxidante de γ-CD·gingerois.
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Abstract 
 
Key words Cyclodextrins, inclusion complexes, ginger rhizome extract, gingerols, Cistus ladanifer 
essential oil 
 
Abstract Cyclodextrin inclusion of multi-component guests such as essential oils and plant extracts 
is a current topic of research. These systems are usefull for a number of applications in 
food, cosmetic and pharmaceutical industries. The present work focus on two of these 
systems, having as guests Cistus ladanifer essential oil and a mixture of gingerols obtained 
from fresh ginger rhizome. 
The C. ladanifer essential oil composition was elucidated by GC-MS, which allowed 
identifying 94.3 % of the components and to establish the approximate Mw at 143.7 g.mol-1. 
The oil was subsequently included into beta and gamma cyclodextrins (β and γ-CDs) by 
co-precipitation. Identification of the included components of the oil was done by chloroform 
extraction followed by GC-MS analysis. β-CD preferentially included compounds of higher 
molecular weight, whereas γ-CD included lower molecular weight compounds. Solid state 
analysis of the inclusion complexes comprised infrared spectroscopy (FTIR), {1H} 13C 
CP-MAS RMN and powder X-ray diffraction (PXRD) that suggests the occurrence of 
channel packing for both. 
Gingerols were obtained from fresh ginger by maceration in isopropanone followed by 
column chromatography. The product was analysed by 1H RMN and mass spectrometry 
(ESI-QTOF), revealing a composition of 54.05 % 6-gingerol, 19.45 % 8-gingerol and  
26.5 % 10-gingerol, and a corresponding Mw of 314.7 g.mol-1. The γ-CD·gingerols complex 
was obtained by co-precipitation and characterized by FTIR, {1H} 13C CP-MAS RMN, DSC 
and PXRD. It presented the typical γ-CD complexes packing in the form of infinite channels. 
PXRD data was further treated with a Pawley extraction allowing to identify a tetragonal 
unit cell with the parameters refined at a = b = 23.886(3) Å e c = 23.356(3) Å. The 
antioxidant activity of γ-CD·gingerois and free gingerols, as evaluated by the β-carotene 
bleaching assay, showed similar potencies. Free gingerois and the complex of 
γ-CD·gingerols were employed in fortification of yoghurt, at a concentration of 1% (m/m) of 
gingerol (or its equivalents mass for the complex). A better dispersion into the matrix was 
observed for the γ-CD·gingerols–fortified yogurts in comparison with gingerols-fortified 
samples. The colour of the yoghurts fortified with the complex was almost similar to that of 
plain yoghurt, whereas those fortified with free gingerols had more colour variation in regard 
to plain yoghurt. The storage stability of fortified yoghurts was evaluated through pH 
monitoring and the formation of malodours. No changes in pH or malodours were observed 
for four weeks. In turn, a malodour in simple yoghurt was noticed starting from the second 
to the third week of storage. The antioxidant activity of yoghurts, as measured by the ABTS 
assay, revealed a higher antiradical action for gingerols-fortified and γ-CD·gingerols–
fortified yogurts when compared to that of plain yogurts, with the most promising results 
being registered for the gingerols-fortified samples. These particular results suggest that 
food matrix might interfering the antioxidant activity of γ-CD·gingerols.
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1. Introduction 
 
1.1. Cyclodextrins, from Enzymatic Digest Products to Inclusion Complexes 
 
1.1.1. From Early Discovery till Today: the History and Production of Cyclodextrins 
Cyclodextrins were first described by Villiers, in 18911. Villiers isolated a substance 
from bacterial digest of starch that was resistant to acid hydrolysis and did not show reducing 
properties. This was called “cellulosine”, because it had resemblances to cellulose. Later on, 
Schardinger studied bacillus isolated from cereal based foodstuff, which had the ability to 
form “crystalline dextrin” – the name given by Schardinger to cyclodextrins2. The bacteria 
fed on an aqueous suspension containing only starch to produce a clear solution in 24h at  
50 ºC, enabling the easy formation crystals of cyclodextrins as the water evaporated. In a 
follow-up study, Schardinger perfected the crystallisation process and isolated the bacterial 
strain that affords the cyclodextrins, naming it Bacillus macerans3, being now referred as 
Bacillus firmus after a taxonomical revision. Nowadays, it is known that the production of 
cyclodextrins relies on the action of the enzyme responsible for starch fragmentation and 
cyclisation, named cyclodextringlycosyltranferase (CGTase)4. 
Following the studies of Villiers and Schardinger, other scholars continued to work 
on cyclodextrins, but, until 1935, this field of research underwent a “period of doubt”5. This 
designation was given due to doubts regarding the purity of the dextrins used, as well as the 
structure, which had not yet been well established. From 1935 to 1950, the investigation with 
cyclodextrins reached a “period of maturity” and a consensus on the nomenclature was 
attempted. It was Friedrich Cramer that suggested the nomenclature and the abbreviation for 
cyclodextrins, in his doctoral thesis, in 1949, even though it remained a subject of debate 
until the 1990s5. Alterations involved the use of the Greek alphabet depending on the number 
of glucose units and the use of CD abbreviation for cyclodextrin. This way, the main and 
most common products of the CGTase enzyme, named native cyclodextrins and having six, 
seven or eight α-D-glucose units, are named alpha, beta and gamma (α-CD, β-CD and γ-CD), 
respectively. 
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Figure 1 – Schematic representation of the three most abundant cyclodextrins: α-, β- and γ-CDs (left to 
right). 
 
Cyclodextrins with higher number of glucose units, referred to as large ring 
cyclodextrins (LR-CDs), are less common, although some may also be formed in trace 
amounts by action of CGTase, namely rings with nine (δ-CD), ten (ε-CD) or more glucose 
units6. Currently, LR-CDs with up to 54 glucose units can be produced using a different 
enzyme, amylomaltase, and pea starch as the substrate7. 
 
1.1.2. Structure and Properties of Cyclodextrins 
In cyclodextrins, the α-(1, 4) glucose units are linked at C1(n)-O4(n-1)-C4(n-1), where n 
is the number of a glucose unit. This connection and the bond between C6-O6 of the glucose 
units are the only conformational freedom points of CDs8. Thus, there is possibility of slight 
variation in the angles and torsion these bonds, resulting in non-equivalent carbons in the 
different monomer units. The conformation of 4C1 α-D-glucopyranose units causes all 
secondary hydroxyl groups to be positioned at the wider rim of the ring and the primary ones 
to face the narrower rim9. The cavity is lined with H3 and H5 hydrogens and the glycosidic 
oxygen bridges, thus having hydrophobic character. 
The height of all native cyclodextrins is constant – 7.9 Å9 – and only the diameter 
changes as a result of them having different number of glucose units. The differences in their 
properties arise this precisely from the different number of glucose units, implying different 
diameters and cavity volumes (Table 1). These two characteristics make it possible to form 
inclusion complexes with hydrophobic molecules having adequate shape and polarity to be 
encapsulated. Note also that in this process it is possible to encapsulate several guest 
molecules. The inclusion complexation process will be detailed in subsection 1.1.4. 
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Table 1 – Physico-chemical and structural properties of native cyclodextrins. Adapted from J. Szejtli9. 
Property α-CD β-CD γ-CD 
Number of glucose units 6 7 8 
Molecular weight, g/mol 972 1135 1297 
Solubility in water at room temperature, g/100 mL 14.5 1.85 23.2 
Diameter of the cavity, Å 4.7 – 5.3 6.0 – 6.5 7.5 – 8.3 
Diameter of the outer periphery, Å 14.6 ± 0.4 15.4 ± 0.4 17.5 ± 0.4 
Approximated volume of cavity, Å3 174 262 427 
 
In particular, β-CD has a much lower aqueous solubility than the other two native 
CDs, which results from the intramolecular hydrogen bonds formed between the secondary 
hydroxyl groups of all its glucose units10. The chirality of the glucose units of β-CD induces 
energy differences between geometries with different orientation of the co-operativity of 
hydrogen bonds. These intramolecular hydrogen bonds are homodromic, forming a closed, 
monodirectional circle which contributes to stabilize the macrocyclic conformation of β-CD, 
leading to a lower solubility. 
Native cyclodextrins can be chemically modified to modulate their physico-chemical 
and biological properties – cavity depth, reactivity and polarity. These reactions involve the 
hydroxyls of the primary and/or the secondary rims11. Modified cyclodextrins can be more 
water soluble and useful as enzyme mimics, because the substitute groups that are linked to 
the cyclodextrin can act through molecular recognition. The use of modified cyclodextrins 
increases their application range, because, in addition to acting as delivery systems, they 
increase bioavailability and activity of drug, as they are more soluble than their native ones. 
 
1.1.3. Safety of Cyclodextrins 
α-CD is approved by the WHO/FAO Joint Expert Committee on Food Additives 
(JEFCA) as a food additive since 200212 and as a dietary fiber since 200613, in both uses 
having an acceptable daily intake (ADI) “not specified”, which means that it may be used in 
food in unrestricted quantities. In the United States, it has been the last native cyclodextrin 
to be awarded the GRAS status in 200414. β-CD is the only native cyclodextrin with 
consumption restrictions. In 2001, β-CD was classified as GRAS15, but it has a daily intake 
limit (ADI) of 5 mg/kg16. Both α- and β-CDs are indigestible in vivo, while γ-CD is 
considered a slowly digestible carbohydrate17. For this reason, γ-CD was the first native CD 
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to be approved for uses in foodstuff in countries outside of Japan. In 1999, the JEFCA 
approved γ-CD as a food additive18 and it received the GRAS status in the following year19. 
Nowadays, β-CD is still listed by its food additive number – E45920. 
In in Australia, New Zealand and Europe, α- and γ-CDs are denominated as “Novel 
Food”, which means that the use of their additive number is not required and they can be 
listed by their name21.The Food Standards Australia and New Zealand (FSANZ) has 
accepted α- and γ-CD as novel food in 200422 and in 200323, respectively. In Europe, the use 
of the term novel food for cyclodextrins was late applied. α-CD was accepted as novel food 
in 200824 and γ-CD has this nomination since 201225. In Japan, native CDs are used without 
restriction and have made their way into a very large number of products26. 
Chemically modified cyclodextrins are also subject to regulatory control and safety 
approval. In the European Union, this cyclodextrins are regulated as excipients and their use 
is approved by the European Medicines Agency according to the delivery route. 
2-hydroxypropyl-β-cyclodextrin (HPβCD) is considered safe for consumption, although 
there are references to some biochemical changes in the body, namely the increase of some 
plasma levels of enzymes, on test animals (rats, mice and dogs), and diarrhea, in humans27, 
while FDA only approved its use for topical route28. 
In Canada, native cyclodextrins are classified as synthetic duplicates of natural 
products and they have been approved as ‘natural medicinal ingredients’ (NMIs) since 2011 
and ‘natural health products’ (NHPs) with the function of ‘controlled release vehicle’ and 
currently they are registered as emulsifying, sequestering, stabilising and encapsulating 
agents. HPβCD is registered as an emulsion stabiliser and sequestering agent and DIMEB 
as a sequestering, stabilising and encapsulating agent29. 
In addition to being able to be used in the formulation of certain foodstuffs with 
stabilizing and emulsifying properties, the cyclodextrins may be present in cosmetic and 
daily care products. It is known from food applications that CDs are not dangerous for human 
consumption (the gastrointestinal mucosa does not undergo any kind of irritation reaction 
when in contact with foods containing cyclodextrins)30. However, the outer membrane of 
the skin has a quite different microbial flora, whereby the topical reactions must be evaluated 
considering using CDs in cosmetics. 
Approved cosmetic ingredients are reviewed by the Cosmetic Ingredient Review 
Expert Panel, an independent, non-profit scientific body established in 1976 that regularly 
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examines and establishes the safety of ingredients31. This entity has approved native CDs, 
HPβCD, HEβCD, Rameb and mixtures of native CDs with laurate and 
hydroxypropyltrimonium chloride as safe ingredients for cosmetics32. 
For dermal products, native cyclodextrins are considered safe at concentrations up to 
0.1%, as well as HPβCD that is also considered safe without mentioned dose restriction33. 
The methylated-CD 2-hydroxypropyl-γ-cyclodextrin (HPγCD) was approved as an inactive 
ingredient by FDA, but it is limited to the topical route and to a maximal concentration of 
1.5% (w/v)28, respectively. 
A comparative study with native and chemically modified CDs, namely β-CD, γ-CD, 
Rameb, Dimeb, Trimeb, HPβCD and HPγCD, using a bioassay named corneoxenometry in 
healthy volunteers showed no harmful effects on the skin34. This bioassay measures the 
compatibility of xenobiotics with the stratum corneum and the manifestation of irritation or 
any alteration in the stratum corneum structure. The corneoxenometry suggested that all 
cyclodextrins tested are well tolerated by the skin.  
 
1.1.4. Inclusion Complexes – the Supramolecular Assembly of Cyclodextrins 
In aqueous solution, the cavity of cyclodextrins is occupied by water molecules, 
which, due to their polarity, are energetically unfavoured and thus easily replaced by a less 
polar guest molecule. This process is denominated molecular encapsulation and it is not a 
chemical reaction9,35. In particular, the hydrophobic or Van der Waals forces keep the guest 
included in the cyclodextrin, and the various cyclodextrins interact via hydrogen bonds. 
Typically, the formation of an inclusion complex causes the decrease of cyclodextrins ring 
strain and leads to a more stable and lower energy state. A good binding between host and 
guest depends on the volume of the cavity of the cyclodextrin and the size of the guest as 
well as on specific local interactions between surface atoms. Even though the inclusion 
complex is a stable adduct, a dynamic equilibrium between cyclodextrin and guest is 
achieved in the free and encapsulated forms, when the complex is in solution. 
Usually, water is the solvent of choice to solubilise CDs. Unfortunately, as the guest 
molecule is hydrophobic, this molecule needs to be dissolved with a co-solvent. In general, 
the host:guest ration is 1:1, but other ratios can occur such as 2:1, 1:2, 2:2 and even multiple 
stoichiometries, though these are quite rare9. In the inclusion complex, the guest molecules 
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are wrapped individually or in pairs (depending on the stoichiometry of inclusion) by the 
CD cavity and therefore their behaviour is dramatically altered. 
The guest molecule can be solid, liquid or gaseous, and can comport a variety of 
chemical structures – straight or branched compounds – and families – aliphatics, aldehydes, 
ketones, alcohols, organic acids, fatty acids, aromatics, gases, halogens, oxyacids and 
amines36. The great variety of compounds that can act as guest allows inclusion complexes 
of cyclodextrins to be applied in products that generally do not have CDs in their 
composition and this use increases the quality of the product. 
In the literature, there are already several essential oil encapsulated37. Table 2 
presents several essential oils inclusion complexes using β-CD, as well as HPβCD, with the 
effect observed. The use of these cyclodextrins is due to the fact that the cavity has the size 
indicated for the complexation. On the other hand, the use of the modified cyclodextrin 
allows a more soluble final product to be obtained in water, since the solubility of HPβCD 
is higher than that of β-CD. 
 
Table 2 – Essential oil (EO) inclusion complexes in β-CD and HPβCD. 
Cyclodextrin Guest – Essential Oil Ratio Observation(s)/Effect(s) Ref 
β-CD Cinnamonum verum 1:1 Mask taste, increase solubility and antimicrobial 
action 
38 
Coriandrum sativum dns Same antioxidant activity than guest alone 39 
Eugenia caryophyllata 1:1 Mask taste, increase solubility and antimicrobial 
action. 
38 
Lavandula angustifolia dns Formation of controlled release systems for the 
delivery of essential oil used as ambient odours. 
40 
Lavandula spica dns Increase of durability of volatility fragrance 
compounds on textiles. 
41 
Mentha piperita 1:1 Controlled release of aroma compounds. 42 
Satureja montana 1:1 Increase solubility, antioxidant, antibacterial and 
antifungal actions. 
43 
Thymus vulgaris 1:1 Increase solubility, improve antimicrobial action, 
by decreasing the needed concentration, protect 
EOs from degradation and convert into a powder. 
44 
HPβCD Lavandula viridis dns Antioxidant activity of the EO/HPβCD 
complexes were more stable over 30 days, at 4ºC 
than comparative β-CD complexes. 
45 
Lavandula pedunculata dns 
Thymus lotocephalus dns 
Lippia gracilis dns Possible application at the breeding site of the 
dengue mosquito. 
46 
Note: dns – data not showed. 
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Cyclodextrins may further have the ability to select the type of molecule to include, 
i.e., the hydrophobic cavity may be selective in behavior. Testing different cyclodextrins 
permit determining which one forms the strongest inclusion complex. This procedure was 
performed for the essential oil of basil and tarragon47. 
 
1.1.5. Advantages of Cyclodextrins and Inclusion Complexes Application 
The solubilising, stabilising and protecting actions of both native and chemically 
modified CDs on the included guests make them useful for several applications and are 
currently ubiquitous in a variety of products, including foodstuff48, pharmaceuticals49 and 
cosmetics50. There is a great variety of possible guest molecules, being preferentially apolar, 
low solubility drugs, volatile compounds warranting stabilization or light-sensitive 
compounds. 
Both in the singular form and as inclusion complex, the native and modified 
cyclodextrins are applied in the various areas of product development. Inclusion of aromatic 
molecules is one of the earliest applications of cyclodextrins. These CDs remain among the 
most widely used, as demonstrated by the large variety available from commercial sources. 
The hydrophilicity, small size and adequate geometry of the fragrance molecules make them 
excellent guests for cyclodextrins. 
CD are presently used with a variety of functions, from solubilising agents to 
formulation helpers. The most obvious advantage of using ICs is the increase in the solubility 
of guests and they can also stabilized labile guests against the degradative effects of 
oxidation, visible or UV light and heat50,51. They can provide controlled release of active 
ingredients, reduce or prevent skin and gastric irritation and prevent interactions between 
formulation ingredients, because they allow the physical isolation of incompatible 
compounds, avoiding undesirable interactions that would alter the properties of the product. 
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1.1.5.1. Application of Cyclodextrins in Foodstuff 
CDs are used as preservatives in a variety of spices, flavors, tea, vinegar and seeds, 
or as emulsifying enhancers in whipped creams, mayonnaise and dressings. With the 
advancement of technological developments, CDs and their ICs are more and more 
employed in the food industry as they help increase shelf life and allow microbiological 
protection. 
β-CD can be used as a partial fat substitute52. The effect of β-CD on the 
flavour-release profiles of non-fat flavoured milks and yogurts was analysed by headspace 
gas chromatography to reveal that these products mimic quite well their corresponding 
higher-fat-content counterparts. Then, a sensory evaluation study was carried out yogurts 
and salad dressings. The panel found that the addition of β-CD to the non-fat yogurt did not 
provide it with the flavour and texture matching those of the fat-containing yogurts, but when 
evaluating salad dressings (Italian- and ranch-style) they found that flavour profiles of 
non-fat dressings were indeed more similar to the corresponding full-fat products. β-CD 
polymers are used to process milk53,54 and butter55,56, by sequestering cholesterol that gets 
easily included in the cyclodextrin’ cavity and affording free- or low-cholesterol foods. On 
the other hand, γ-CD is commonly incorporated into the dough of baked products48. 
Cyclodextrin in breads, rolls, muffins and bagels is labelled under the category of 
preservative. An example is HealthyLife’s whole wheat bread (by Lewis Bakeries Inc.)57. 
Cyclodextrins are also applied in beverages. α-CD permits an easy incorporation of 
a desired molecule without causing changes in the appearance of the beverage, as α-CD is 
water soluble and its inclusion complexes dissolve to from crystalline solutions48. β-CD 
allows masking undesired flavours, for instance, the bitterness of ginseng-based drinks58. 
Addition of β-CD with or without the combination with γ-CD was shown to reduce the bitter 
flavour of ginseng by roughly one half, when incorporated into a ginseng-based energy drink 
formulation. 
Among commercially available inclusion complexes, γ-CD·curcumin is already sold 
by Wacker Chemie and it has approved use for dietary supplement59. There are also patents 
relating to food products with cyclodextrins. The application of γ-CD in a drink was 
patented60 as well as a nutritional product containing γ-CD in a fraction of 5 to 100 wt.% of 
the total carbohydrates, designed for women with gestational diabetes and claimed to reduce 
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the postprandial insulin secretion in order to normalize blood glucose levels and prevent 
night-time hypoglycaemia61. 
Upon ingestion, native CDs are practically not absorbed, because of their bulky and 
hydrophilic nature. Absorption by passive diffusion is neglectable48. α-CD and β-CD are 
resistant to stomach acid and to salivary and pancreatic enzyme digestion, while γ-CD is 
digested partly by amylases in the large intestine62. In Windsar rats, α-CD ring opening was 
shown to occur by action of the gut flora (microbial enzymes) to form linear 
malto-oligosaccharides63,64. These products are hydrolyzed and fermented by routes similar 
to those of resistant starch. Consequences of these fermentation processes, bloating, include 
flatulence, nausea and diarrhea which were observed in rats and beagle subjected to regular 
consumption of α-CD (between 4 and 13 weeks)65,66. These symptoms were also reported 
by about 30% of the human subjects participating in the study on the effects of ingestion of 
cooked rice with α-CD67. 
γ-CD, in turn, has a good gastrointestinal tolerability. A double-blind 
placebo-controlled, cross-over, randomized study with 24 volunteers ingesting yogurt with 
γ-CD (8% m/m) revealed that the yogurt was well tolerated and did not cause any 
gastrointestinal discomfort68. In other study, consumption 25 g of γ-CD dissolved into a 
drink of 240 mL caused no significant side effects in the 24 hours after ingestion69. 
α-CD can associated with lipid molecules, forming inclusion complexes which leads 
to a reduction in the problems associated with the passage of free fat through the 
gastrointestinal tract (steatorrhea and intestinal incontinence) and to an improvement in the 
lipid profile in the blood70. In healthy humans, the consume of α-CD in a meal provides a 
reduction in postprandial triglycerides levels71, in total and LDL cholesterol (LDL = 
low-density lipoprotein) and in body weight70. In rats, a diet with 21% milk fat and 2.1% of 
α-CD showed reduced seric proatherogenic lipoproteins and trans-fatty acids72.  
Cyclodextrins also act on glycemic index. α-CD is already patented in bread, that 
allows the decrease for glycemic index, as with the consumption of this bread, the blood 
glucose concentration did not tend to rise above 110 mg/dL and the blood insulin 
concentration did not increase above 65 μUI/mL, instead of 120 μUI/mL observed on plain 
bread consumption73. Relatively to γ-CD, in a study with 32 healthy adults (double-masked, 
randomized, crossover design), the intake of a drink containing 25 g of γ-CD on 240 mL of 
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drink was shown to effectively lower post-prandial glycemia and insulinemia when 
compared to an equivalent maltodextrin-containing drink74. 
 
1.1.5.2. Application of Cyclodextrins in Cosmetics 
The largest organ in the human body, the skin, acts as tough, flexible, structural 
barrier to invasion. It has its own flora, that may vary under the influence of multiple factors 
such as pH, temperature, presence of sebum, fatty acids and salt75. This structured barrier 
can suffer a break and cosmetic products are important to keep it clean, structured and safe. 
Therefore, the number one priority for cosmetic and personal care products companies and 
drugs and pharmaceutical companies is consumer safety. The products conceived to be 
applied topically on the skin can be classified as cosmetics or topical drugs. 
Cosmetics, known as products that are intended to clean or to enhance beauty, are 
not regulated by the United States Food and Drug Administration (FDA)76, only requiring 
the FDA approval in case of having colour additives. On the other hand, sunscreens, 
antiperspirants, diapers ointments and treatments for dandruff or acne are cosmetic drugs 
and they require both cosmetic and drug approval. Cosmetic are regulated by the Federal 
Food, Drug, and Cosmetic Act (FD&C Act) and it is required that “every cosmetic and 
personal care product and its ingredients be substantiated for safety before going to the 
market, and that they contain no prohibited ingredients”77. This means that ultimately the 
safety of cosmetics is the responsibility of companies. Allergies and rashes can be reported 
to the FD&C Act, but, as this depends on the consumer itself, it is not mandatory for the 
company to assume the occurrence. 
From 2000 until the present day, cyclodextrins are gaining more relevance as 
technological solutions for dermopharmaceutical and cosmetic products78. In the cosmetics, 
CDs were used as masking agents for components with unpleasant aroma and stabilising 
active ingredients. Generally, CDs are listed in the ingredients as cyclodextrin and they are 
found in a variety of anti-aging products that contain potent, yet unstable, antioxidant 
ingredients, such as anti-aging treatments, facial moisturisers or lotions, sunscreens, 
cleansers, eye creams, deodorants and self-tanners.  
Cyclodextrins, either pure or in the form of inclusion complexes, are widely used in 
cosmetic products. As cosmetics are generally placed at room temperature, are daily used by 
healthy people over long periods and are mainly composed of oleaginous raw materials, 
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ultraviolet absorbents, antioxidants, colouring materials and fragrance materials, among 
others79, most of them easily perishable, when used in the free form, CDs help stabilise 
components, in other to ensure the constancy, security and safety of the product. Even though 
it is known that cyclodextrins are used on the formulation of skin products, the quantity of 
cyclodextrins applied is not really known, because there are no references of defined 
quantities in patent documents. At the same time, patent documents do not specify for which 
purpose cyclodextrins are applied in the product. 
The delivery of drugs through the skin may be enhanced by improving the release of 
drug from the transdermal pharmaceutical preparation bases, the increasing of the flux of 
drug through the skin or by the retention of drug in the skin, the increasing in topical or 
localized skin delivery or tissue targeting of drug or a combination of the previous factors. 
Parent cyclodextrins and hydrophilic derivatives can affect the permeability of drugs through 
the skin, the bioconversion of drugs in the viable skin and the topical irritation caused by 
drugs80,81. The parent cyclodextrins and the modified HPβCD are not able to induce 
disruption of the stratum corneum82, as they are too large to be able to penetrate deeply83,84, 
which implicates that they are used a as a vehicle for the guest lipophilic molecules that can 
compete with the membrane constituents. Table 3 shows the studied effect of native and 
modified cyclodextrins on the permeability of compounds through the skin, both in vitro and 
in vivo. 
 
Table 3 – Effect of native and modified cyclodextrins in permeability of drugs though the skin. 
Cyclodextrin Effect(s) Drug 
α-CD Increase the in vitro transdermal 
permeability. 
Dehydroepiandrosterone85 
β-CD Increase the in vitro skin permeation. Betamethasone86, 4-Biphenylacetic acid87, 
Dexamethasone88, Flurbiprofen89 
γ-CD Increase the permeation in a skin-friendly 
way. 
Beclomethasone dipropionate90, 
Fludrocortisone acetate91 
HPβCD Increase the in vitro skin permeation. Avobenzone92, Curcumin93, Dexamethasone88, 
Estradiol94, Ketoprofen95, Oxybenzone96 97 
Rameb Improve the solubility and permeation; 
reduce the skin barrier function. 
Bupranolol98 
 
Cyclodextrin inclusion allows turning an oily ingredient into a solid, that is easier to 
manipulate and often more resistant to thermal degradation99. This way, plant essential oils 
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and liquid botanical extracts can be turned into powders and their volatility is strongly 
reduced. Besides these advantages, and given that the essential oil is a mixture of 
compounds, the cyclodextrin may perform a selective encapsulation of a few components. 
In the case of these being minor components in the pure essential oil, they may then become 
major components in the inclusion complex, which may lead to the emergence of interesting 
properties that in the oil were masked by the existence of in larger quantities of other 
components that do not manifest this property. 
ICs are already commercially available in order to use them as ingredients in the 
cosmetic and pharmaceutical cosmetic (Table 4). Furthermore, it is known that there are 
several products already marketed with ICs as well as patents. 
 
Table 4 – Cyclodextrin inclusion complexes used in commercially available cosmetic and medicines. 
Inclusion Complex Use Ref 
β-CD·citral Used as a raw material in the perfume industry. 100 
γ-CD·co-enzyme Q10 Recommended for use in cosmetic nutrition, as it is well absorbed by the 
skin in the presence of dipotassium glycyrrhizate. 
101,102 
2γ-CD·retinol Recommended for personal and skin care, anti-aging and suncare 
products. 
103 
2γ-CD·vitamin E Recommended for products within skin care, anti-aging, self-tanning, 
shaving formulations, coloured cosmetics and sun lotions. 
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Cyclodextrins are used as active ingredients for the entrapment of odours in the 
household deodorant spray “Febreze”105, and in the laundry dryer sheets “Bounce”106. These 
two product lines have come to grow into the largest market applications for CDs in the 
cosmetics & toiletries branch. CDs are also present in sun lotions, protecting and stabilising 
the chemicals against precocious degradation from light and the aromatic compounds thus 
bringing a sustained release effect107. 
In addition to these products, there are still patents related to the use of cyclodextrins 
in cosmetics and in daily care products. A set of aqueous compositions based on 
cyclodextrins (and polymers as thickeners), which may or may not contain adjuvant 
adsorbent and antimicrobial agents, is claimed to reduce body odours108 . In another patent, 
compositions based on cyclodextrins and surfactants are claimed to entrap odours by 
spraying on surfaces109. In a toothpaste formulation, β-CD is used in tandem with papain to 
achieve ‘rapid removal of bad breath’110.Transdermal films for the delivery of active 
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substances, having a composite of HPβCD, polyvinyl alcohol and chitosanes as the main 
ingredients, are already patented in China111. DIMEB and RAMEB are patented for 
promoting the penetration of vitamin A or its esthers in compositions intended for cosmetics 
or dermatology care, to ‘regulate the cell metabolism of the skin, and/or preserve or restore 
a good physiological skin condition and/or improve the tone, firmness and elasticity of the 
skin, and/or delay the appearance of wrinkles or reduce their depth’112. 
In cosmetic formulations, in addition to the previously mentioned advantage, CDs 
modulate of the properties of creams and gels82, and are good solubilizers for oily 
components since they form transparent aqueous solutions, whereas other dissolution agents 
typically cause cloudiness99. CDs also help formulate otherwise non-compatible components 
by inclusion and ‘mask’ of one of these components. CDs also help to reduce skin redness 
and irritation caused by active compounds, as celecoxib113and tretinoin114, and making 
retinoids better tolerated115. 
Regarding aromas, CDs help mask unpleasant odours or flavours (of active 
ingredients such as omega-3 and omega-6 oils)116,117, and they are excellent aroma 
stabilizers, helping maintain flavour in lipsticks, perfumes and room fresheners118. Inclusion 
complexes of aromatic compounds such as essential oils or their components present, besides 
the longer release of aroma, a much higher storage time and sheld-life. Hydrophilic gels 
containing HPβCD inclusion complexes with linalool, the main terpenic compound 
associated with lavender fragrance, and benzyl acetate, an aromatic compound associated 
with jasmine fragrance, were shown to retain the fragrance for over six months, while the 
same compositions having only linalool or benzyl acetate lost the fragrance after two 
months99. Sustained-release activity was demonstrated in vitro for eugenol. The amount of 
this compound permeating excised skin 24h after application was roughly five times lower 
for HPβCD·eugenol than for pure eugenol119. Sustained release properties were also reported 
for β-CD·trans-anethole120, HPβCD·ionone (sweet osmanthus flower fragrance)121 and 
HPβCD·geraniol122. In parallel, compounds with a very high affinity towards the 
cyclodextrin cavity will dissociate at a very slow rate from the complex and thus these ICs 
will exhibit sustained release of the drug or active ingredient when applied on the skin. 
The formation of IC lead to the protection of guest molecules as they can suffer 
several reactive reaction and this way the hydrolysis, oxidation, isomerisation, 
polymerisation, and enzymatic decomposition reactions are eliminated or minimised, 
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resulting in extended shelf-life for the products containing ICs123. This way, consumer safety 
is also increased by ensuring that all the components have their characteristics unaltered for 
a longer time. At the same time, the organoleptic characteristics do not change, which 
enables the continuous acceptance of the food or the cosmetic product. Considering all these 
advantages, the practical utility of inclusion complexes in food and cosmetics is self-evident. 
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1.2. Cistus ladanifer, a Mediterranean Plant 
Cistus ladanifer, sometimes also referred to as Cistus ladaniferus124, is a bushy plant 
of the genus Cistus and to subgenus Leucocistus. It is part of the Cistaceae family, a large 
family of Mediterranean plants comprising almost 200 species of shrubs125. Cistus ladanifer 
is the scientific name for the rockrose plant, known for its pentameric white flowers having 
a crimson spot in the base of the petals and a small yellow eye. The species of this family 
include fragrant and sweet smelling plants that are used in cosmetic and the perfume 
industry126 and the leaves and the steams secrete an abundant exudate consisting of 
secondary metabolites, bioactive compounds, which are widely appreciated for the potential 
beneficial health effects. 
 
 
Figure 2 – Cistus ladanifer flower126. 
 
1.2.1. Geographic Distribution 
Cistus ladanifer grows all over the world, being particularly abundant in the 
Mediterranean region and the Iberian Peninsula127. This plant grows preferably on volcanic 
sandstone soil and in continental climate regions. In Portugal, it is possible to identify several 
areas where this species abounds. In a study carried out in 2008, 23 samples of C. ladanifer 
were collected in the Faro district, in the south of Portugal128. C. ladanifer also thrives near 
mining areas such as Caveira, Lousal and São Domingos, in the Alentejo region129. Note that 
albeit it is mainly found in the South of Portugal, it may also be spotted in some areas of the 
North of Portugal130,131. 
Figure 3 (adapted from online information132) depicts the distribution of C. ladanifer 
species and subspecies in the Mediterranean area133. This plant is distributed over the south 
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of Portugal, north Morocco, central and south Spain, south France, Corsica, north Algeria 
and Cyprus. 
 
 
Figure 3 – Distribution of Cistus Species and Subspecies in the Mediterranean geographic area133. 
 
1.2.2. Chemical Composition of Cistus ladanifer 
Depending on the solvents used and the type of extraction and conditions that are 
applied, it is possible to obtain extracts with different compositions: an extract rich in 
flavonoids is commonly obtained with water or/and other polar solvents such as ethanol and 
methanol, or even acetone; one rich in terpenes is normally obtained with non-polar solvents 
and hydrodistillation method. There are two types of terpenic extracts: the essential oil and 
the labdanum, which is thicker than the essential oil. However, it should be noted that any 
type of distillation approach can lead to the thermal degradation of the compounds or to 
formation of other compounds. 
 
1.2.2.1. Cistus ladanifer Flavonoids 
The exudate of Cistus ladanifer is composed fundamentally of compounds of 
phenolic origin134,135. The composition of the exudate varies the season, being richer in 
flavonoids during the summer and poorer in the winter136. Indeed, the summer season causes 
C. ladanifer to be exposed to various types of stress, such as high temperature and levels of 
UV, which leads to further development of secondary compounds. 
Using water, ethanol, methanol or acetone, it is possible to obtain a flavonoid extract, 
which composition variates due to the solvent used137. The phenolic compounds synthesized 
by C. ladanifer are mainly aglycone flavonoids, namely apigenin, kaempferol 3-methyl 
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ether, apigenin 4'-methyl ether, apigenin 7-methyl ether and kaempferol 3,7-di-O-methyl 
ether, that overall can represent about 6% and 26% of the dry weight of the exudate134. 
The phenolic content of the extracts also differ according to the raw material used: 
flowers, fruits, stems or leaves138. Flowers were reported to have the highest phenolic 
content, optimally when using methanol, ethanol:water (50:50), methanol:water (50:50) or 
acetonitrile. In fruits, phenolic content was best extracted with water, ethanol or 
methanol:water (50:50). From stem, extraction was more rentable using ethanol or 
acetonitrile and, from leaves, extraction was best achieved using water, ethanol or 
methanol:water (50:50).  
Besides the high content in flavonoids, C. ladanifer also has tocopherols, sugars and 
fatty acids in its composition139. Some terpenes may also be found in the flavonoid exudate 
as a result of the extraction method135. They represent 1% to 2% of dry weight of the exudate 
and they are diterpenes (oxocativic acid, 6-acetoxy-7-oxo-8-labden-15-oic acid and 
7-oxo-8-labden-15-oic acid). 
 
1.2.2.2. Labdanum 
Labdanum is a rich sticky brown resin obtained from the cistus shrubs and it has a 
long history of use in herbal medicine and as a perfume ingredient. This resin is a natural 
fixer of essential oils and of the odoriferous essence obtained from the leaves130. The crude 
gum of labdanum is obtained by treating the plant with hot alkaline water to remove all 
waxes on the surface resinous matter and oily parts from the plant. Labdanum can be 
subdivided into three portions, depending on the extraction performed: the resinoid, that is 
obtained by steam distillation of the crude gum with ethanol140, the concrete, that 
corresponds to the extract of the whole plant with hexane, and the absolute, obtained by 
alcohol extraction of the concrete141. 
The main components of resinoid labdanum are ledene, viridiflorol, cubeban-11-ol, 
borneol, copaborneol, bornyl acetate, trans-pinocarveol, eugenol, allo-aromadendrene and 
myrtenol140. These compounds are isoprene derivatives with fifteen to twenty carbons. In 
another study, the labdanolic acid, an important precursor of ambrox, a fixative perfume with 
amber odour widely used in the industry, was also identified141. Waxes can also be found in 
the resinoid and concrete. 
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1.2.2.3. Essential Oil of Cistus ladanifer  
Cistus ladanifer essential oil is a mixture of volatile compounds with a strong odour. 
It is mainly constituted by secondary metabolites of the aromatic plant rockrose. 
The essential oil is suitable for usage in perfumes, because it has a reminiscent 
fragrance of gray amber, which blends well with ambar and fern fregrances126. It can be 
obtained by a wide variety of methods. Extraction from fresh plant material by distillation 
for four hours yielded 0.3-0.4% (m/v) of essential oil
141, but the yield may be influenced by 
other factors, since a yield of 0.63% was reported for a three-hour extraction142. The essential 
oil may also be isolated by solvent extraction130, supercritical carbon dioxide143, steam 
distillation144 and hydrodistillation131, as listed in Table 5. A careful analysis of this tables 
allows noting the strong variation in the main components of C. ladanifer essential oil, which 
depend not only on the method of extraction, but also on geoclimatic factors such as soil 
composition, temperature and humidity, and on the stage of the vegetative cycle and the part 
of the plant used. Notably, the presence of α-pinene in almost all samples of essential oil is 
observed, as well as viridiflorol, verbanone and 2,2,6-trimethylcyclohexanone. 
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Table 5 – Summary of different extraction methods for obtaining essential oil of Cistus ladanifer, emphasising 
the main constituents that are obtained. Sample location and collection season are detailed, as well as the 
extraction condition. NC refers to the number of compounds of each sample. 
Sample  Extraction Analysis NC Main compounds Ref 
Corsica, Spain£ Hydrodistillation (24h) GC 
13C-NMR 
45 α-pinene, viridiflorol, ledol, 
bornyl acetate 
145 
Douro, 
Portugal 
(March) 
Hydrodistillation (24h) GC-MS, 
GC-sniffing, 
GC-MS-FID 
14 Acetophenone, borneol, 
2-phenylethanol, 
2,2,6-trimethylcyclohexanone 
130 
Tafoughalt, 
Morocco (May) 
Hydrodistillation (5h) GC-MS 28 Camphene, borneol, 
terpin-4-ol, α-pinene, 
2,2,6-trimethylcyclohexanone 
138 
Tanger, 
Morocco 
(August) 
Hydrodistillation (4h) GC-MS 68 α-pinene, camphene, bornyl 
acetate, ledol, viridiflorol 
2,2,6-trimethylcyclohexanone 
141 
North Morocco 
(vegetative 
period) 
Hydrodistillation (3h) GC-FID 
GC-MS 
58 1,8-cineole, viridiflorol, 
γ-terpineol 
146 
Central, Spain 
(October) 
Hydrodistillation (3h) GC-FID 
GC-MS 
48 trans-pinocarveol, α-pinene 
viridiflorol, bornyl acetate, 
terpinen-4-ol, 
2(10)-pinen-3-one, 
p-mentha-1,5-dien-8-ol,  
147 
Centre-interior 
Portugal 
(July-August) 
Hydrodistillation (2h) GC-FID 
GC-MS 
25*§ Viridiflorol, globulol, α-pinene 131 
North Portugal 
(July-August) 
Hydrodistillation (2h) GC-FID 
GC-MS 
24 f 
18 d*§ 
Viridiflorol, globulol, 
15-nor-labdan-8-ol 
131 
Massif de 
l’Estérel, 
France (May) 
Steam distillation (2h) GC-MS 22 α-pinene, viridiflorol 
verbanone, 
2,2,6-trimethylcyclohexanone 
144 
Ciudad Real, 
Spain (July) 
Supercritical CO2 (9 
MPa, 40 ºC, dp = 0.30 
mm, F =0.7 kg/hr) 
GC-FID 41 Camphor, α-pinene, borneol, 
camphene, γ-terpinene, thymol 
143 
Mirandela, 
Portugal (July) 
Pentane simultaneous 
distillation-extraction 
(1h, 40 ºC) 
HS-SPME 
GC-FID 
4# α-pinene, bornyl acetate, 
borneol, 
2,2,6-trimethylcyclohexanone 
148 
São Domingos, 
& Corte do 
Pinto, Portugal 
(April) 
Hexane extraction 
(30 minutes at 100 ºC, 
1.38 MPa) 
GC-MS 32& Benzenepropanoic acid, 
viridiflorol, verbanone, 
globulol, α-pinene 
149 
Note: 
£ – without reference to the season, * – not all compounds identified, 
§ – comparative study between two different places and fresh (f) or dry (d) samples, 
# – used ten target compounds and identified four of them in the sample, 
& – same compounds identified but in different percentage. 
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1.2.3. Compounds of Cistus ladanifer Essential Oil with Known Biological Activity 
C. ladanifer essential oil is used in traditional medicine for the treatment of various 
skin diseases, as an anti-diarrheic and as anti-inflammatory agent139. The medicinal 
properties are related to the presence of various active components, of which three have 
already been studied isolatedly. 
 
1.2.3.1. α-Pinene 
Alpha-pinene (2,6,6-trimethylbicyclo(3.1.1)-2-hept-2-ene) (Figure 4) is an organic 
terpene compound with anti-inflammatory properties. It is found in the oils of a variety of 
plants (Table 6), with highlight to coniferous trees of which the most well-known is Pinus 
silvestris150,151. It has been approved as a food additive with GRAS status152. 
 
 
Figure 4 – The chemical structure of α-pinene153. 
 
Table 6 – Percentage of α-pinene in different plants essential oils. 
Plant α-pinene (%) Ref 
Cannabis sativa 23 ± 17 154 
Echinophora cinerea 26.54 ± 0.21 155 
Elaeoselinum asclepium 43.9 156 
Eucalyptus camaldulensis 15.6 157 
Ferula tunetana 39.8 158 
Melaleuca leucadendron 12.22 159 
Pinus sylvestris 16.1 151 
Pistacia vera 77.5 160 
Rosmarinus officinalis 19.43 – 21.3 161,162 
 
The anti-inflammatory activity of α-pinene was evaluated under two scenarios of 
induced inflammation. In carrageenan-induced inflammation in mice, α-pinene extract 
(77.5%) from pistachio was administered in various dosages with those of 250 and 500 
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mg/kg being found to reduce inflammation and appearance of gastric lesion160. In a 
cerulein-induced acute pancreatitis in mice, treatment with α-pinene reduced the pancreatitic 
tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6, in vivo, and inhibited 
cerulein-induced cell death and cytokine production, in vitro163. 
A study with mice has indicated a possible application of α-pinene as an anxiolytic 
substance. Mice were submitted to the elevated plus maze test for 10 min, after having 
inhaled α-pinene for 90 min/day for 1 day, 3 days, or 5 days164. The concentrations of 
α-pinene in the brain and liver were quantify and there was significant anxiolytic-like 
activity, which remained constant for the 5 days after inhalation. Thus, α-pinene appears to 
have biological properties of interest. 
 
1.2.3.2. Camphene 
Camphene (IUPAC: 2,2-dimethyl-3-methylidenebicycloheptane) (Figure 5) is a 
bicyclic monoterpene, i.e., an organic compound formed by two fused cycloheptane rings 
(alipahtic six-member rings formed only of carbon atoms)165, occurring in high quantities 
the essential oils of Artemisia terrae-albae166 and Rosmarinus officinalis162 161 and smaller 
or trace amounts in the essential oils of Elaeoselinum asclepium156, Ferula tunetana158, 
Hertia cheirifolia167, Lavandula officinalis168, Cardomom169, Cannabis sativa170. It can be 
used as flavouring agent, having a woody, camphoreous note and there is no safety concern 
at current levels of intake, having an acceptable ADI (concentration not mentioned)171. 
 
 
Figure 5 – The chemical structure of camphene172. 
 
Camphene is currently still under evaluation regarding the medicinal applications, 
but available data already demonstrates a variety of activities. It was shown to have a 
cytoprotective antioxidant effect on t-butylhydroperoxide-stressed alveolar macrophages by 
decreasing lipid peroxidation and the release of NO and reactive oxygen species, while the 
production of superoxide dismutase and glutathione were increased173. This study provides 
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evidence for the traditional medicine claims, ‘the aroma is part of the healing’, since it 
demonstrated that in fact this particularly odoriferous component of C. ladanifer is beneficial 
to the organism. Camphene may also be used as cholesterol-reducing agent, since it was 
demonstrated to inhibit HMG-CoA reductase, the cellular enzyme required for cholesterol 
biosynthesis174.  
In topical formulations, camphene overall well tolerated at doses up to 4%, with no 
irritation observed after a 48-hour closed-patch test175. It also displayed no cytotoxic effects 
on HeLa cells in monolayer culture in vitro test176.  
 
1.2.3.3. p-Cymene 
p-Cymene (IUPAC: 1-methyl-4-(propan-2-yl)benzene) (Figure 6) is an alkylbenzene 
related to a monoterpene found in gymnospermic and angiospermic plants177,178.  
 
 
Figure 6 – The chemical structure of p-cymene179. 
 
This compound is well absorbed through the skin. In studies with 14C-labelled 
p-cymene, the penetration observed was 254 ug/sq cm in 60 minutes180. This maximization 
test was carried out on 25 volunteers, p-cymene was tested at 4% concentration in petrolatum 
and produced no sensitization reactions during 48 hours. 
In mice with LPS-induced acute lung injury, p-cymene reduced significantly the 
oedema, congestion and inflammation by lowering  pro-inflammatory cytokines (TNF-α, 
IL-1β and IL-6), interfering with myeloperoxidase activity, and blocking several 
inflammatory proteins such as mitogen-activated kinase (MAPK)178. 
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1.2.4. Biological Activities of Cistus ladanifer 
The C. ladanifer is probably the most well-characterised of all Cistus species. For 
other Cistus genus, it is established that the flavonoid extract have antioxidant activity and 
protective effect on DNA cleavage181. A study performed in 1993 hypothesised that the 
flavonoid extract from C. ladanifer could protect against the damaging effects of 
near-UV-visible solar radiation136, based on the ability of these flavonoids to absorb light at 
this wavelength interval. However, there is no current reference regarding developments of 
the application of C. ladanifer as a UV filter. 
 
1.2.4.1. Antioxidant Activity 
The flavonoid extract of Cistus ladanifer was extensively study in relation to the 
antioxidant activity, by different tests, such as Folin-Ciocalteu, TEAC, FRAP, ORAC and 
TBARS182. On the other hand, as terpenic compounds have low antioxidant activity, the 
essential oil is not widely study. There is only one reference to a DPPH study for Cistus 
ladanifer essential oil, which is referenced in Table 7, as well as for three phenolic extracts. 
 
Table 7 – EC50 values for DPPH assay for extracts of Cistus ladanifer. 
Extract EC50 /mg/mL Ref 
Hydroethanol* (95:5, v:v) 0.00785§ 
137 
Hydroacetone* (60:40, v:v) 0.03951§ 
Methanol* 100% 0.13 ± 0.22 
142 
Essential oil extract# 36.28 ± 0.36 
Note: 
* – phenolic extract, § – values do not have a confidence range, 
# – extract obtained by hydrodistillation. 
 
Note how the EC50 values of the phenolic extracts differ according to the co-solvent 
used in the extraction. The EC50 is about five times higher for the acetone extract and about 
sixteen times higher for the methanol extract. This means that the phenolic extract of Cistus 
ladanifer using ethanol is the most effective in scavenging the free radical DPPH. On the 
other hand, the value for the essential oil test is about 280 times higher than that of the 
methanol extract, which means that a concentration of about 280 times more is required for 
the oil to have the same effect as the methanol extract; in other words, the methanol extract 
is more effective than the essential oil in the same concentrations. For the others extracts, 
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the difference between the essential oil extract and the ethanol and the acetone extracts would 
be even higher. 
 
1.2.4.2. Antimicrobial Activity 
Cistus ladanifer essential oil has antimicrobial activity on a few bacterial and fungal 
strains141,183, as summarized in Table 8. It should be noted that the data is obtained from two 
different studies, one evaluating the MIC141 and the other one measuring the inhibition 
diameter183. 
 
Table 8 – Antimicrobial activities of Cistus ladanifer essential oil on bacteria and fungi strains. 
Tested Micro-organism Conclusion£ 
Gram 
Negative 
Citrobacter sp.183, Pseudomonas aeruginosa183, Salmonella typhi183 0 
Enterobacter cloacea183, Escherichia coli141,183, 
Klebsiella pneumoneae183, Proteus mirabilis183 
+ 
Gram 
Positive 
Bacilus megaterium141 + 
Listeria monocytogenes183, Staphylococcus aureus183 ++ 
Fungi141 
Aspergillus niger, Botrytis cinerea, Mucor recemosus, 
Verticillium albo-atrum 
+ 
Note: 
£ – the assays performed on the studies where different. 
 
It was considered (+) for the two studies in which antimicrobial action of the essential 
oil was verified. In the case where this action was extensive, it was denominated with (++) 
in which the diameter of inhibition was superior to 10 mm183. 
The essential oil manifested antimicrobial activity against Gram-negative and 
Gram-positive bacteria and fungi strains. Only three Gram-negative bacteria strains did not 
respond to the activity of the essential oil, while Gram-positive bacteria Listeria 
monocytogenes and Staphylococcus aureus displayed an excellent response to the essential 
oil as they exhibited the largest zones of inhibition. Taking into account the properties 
described, it would be interesting to apply C. ladanifer essential oil in cosmetic products. 
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1.2.4.3. Cistus ladanifer Other Biological Activities 
Cistus ladanifer may also have herbicidal activity. An analysis of the areas cultivated 
with this plant showed that flavonoid extracts secreted by its leaves inhibited and delayed 
the germination of herbaceous species. So, Cistus ladanifer essential oil has been tested 
against weed germination. Inhibition was achieved against germination of Amaranthus 
hybridus, Conyza canadensis and Parietaria judaica, at 0.125 μL/mL, and the germination 
of Portulaca oleracea was controlled, using 1 μL/mL, while no effect was observed against 
Chenopodium album147. In this way, Cistus ladanifer essential oil can be used as natural and 
selective herbicide, although the herbicidal concentrations have yet to be established. 
 
1.2.5. Encapsulation of Cistus ladanifer Essential Oil 
For centuries, Cistus ladanifer essential oil has a tradition of use in skin ointments, 
being described in folklore as one of the twelve oils mentioned in the ancient scriptures184 
and claimed to possess regenerative and immuno-regulating abilities. Although these 
properties are still to be demonstrated clinically, Cistus ladanifer is already found in the 
market in an eye-contour formulation, in a blend with other essential oils185. 
As the essential oil has the characteristic fragrance of the plant, the inclusion complex 
may also have this fragrance. The application of the inclusion complex in certain products 
may lead to the consideration that the product also has pharmacological activity, as it may 
occur in creams. The desirable application for this inclusion complex would be in acne 
creams. Acne is caused by the Gram-positive bacteria Propionibacteria acnes, so this cream 
would have a cosmetic and pharmacological application186. A skin application for Cistus 
ladanifer is already patented187. The patent claim improved topical analgesic action for a 
combination of Cistus ladanifer and Cupressus sempervirens terpene-containing extract 
with Acellella oleracea. Note also that no adverse reaction are reported for the oil. Only one 
case of contact dermatitis is reported until now, but it happened for contact with the fresh 
plant188. The symptomatology may thus have been caused by some particular compound or 
by the structures of the plant leaves. 
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1.3. Ginger Rhizome, an Indian Spice 
Zingiber officinale, commonly known as ginger, is an Indian native perennial plant 
with thick tuberous rhizomes and stems rising almost one meter from the ground. Its rhizome 
is widely used in food and traditional oriental medicine189. Dried and grounded to a powder, 
it is used as a spice of flowery-spicy taste and aroma. As a medicinal plant, for example, it 
is used to facilitate digestion, stimulate the circulatory system and help with morning 
sickness and colds. 
 
 
Figure 7 – Ginger rhizome and powder190. 
 
1.3.1. Chemical Composition of Ginger Rhizome 
From the ginger rhizome it is possible to obtain several extracts with varied 
compositions. Using n-hexane and methanol, it is possible to obtain an extract with 6- and 
10-dehydrogingerdione and 6- and 10-gingerdione191, whereas extraction with acetone gets 
6-gingerol192. One of the compounds with the most interest is 6-gingerol, which is widely 
distributed on the plant. Thus, one gram of fresh ginger rhizome and one gram of ginger root 
were grown in different laboratory conditions, as well as stems193, and, in all the extracts, 
6-gingerol was detected, but the one that allows a better extraction is the fresh rhizome of 
ginger. 
The pungent compounds comprise 6-, 8- and 10-gingerols and 6-shogaol. 6-gingerol 
is found in larger amounts and it thus contributes more significantly to this characteristic194. 
The extraction of the various components of the rhizome can be done with the help of 
different solvents. 6-gingerol is more soluble in organic solvents, whereby the use of acetone 
becomes more advantageous for a better yield of 6-gingerol. Using acetone and methanol, 
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7.39% (w/w of fresh ginger) and 5.69% are obtained, respectively
195. In a 1:1 methanol:water 
mixture, 5.15% is obtained, while using water the yield is lowered to 4.58%. 
Variation of temperatures and pressures as well as the flow of carbon dioxide allows 
an increase on extraction yield and the content in 6-gingerol196. The optimum condition for 
ginger oil yield was achieved at extraction pressure of 15 MPa, temperature of 35 ºC and 
CO2 flowrate of 10 g/min, while the optimum condition to obtained 6-gingerol was at 
extraction pressure of 10 MPa, temperature of 35 ºC and CO2 flow rate of 10 g/min. 
An extraction was performed starting from fresh ginger and purchased oleoresin and 
6-gingerol and 6-shogaol were isolated197. Comparing the most common pungent 
compounds, 6-shogaol is found to be higher in oleoresin extract, as well as 8- and 
10-shogaol. These compounds correspond to 6-, 8- and 10-gingerol by conversion, forming 
a C=C double bond with loss of one molecule of water. Considering that the concentration 
of shogaols increases in oleoresin, it is possible to assume that the increase of shogaol 
presents as a change in ginger extract, thus being a method of identifying degradation. 
 
 
Figure 8 – Structure of 6-, 8- and 10-gingerol (left), and 6-, 8- and 10-shogaol (right). 
 
HPLC-UV at 230 nm and 280 nm was performed, as the variation in the absorbance 
allowed to identify the loss of data in the reading at 230 nm197. The variation in the 
absorbance between 230 nm and 500 nm for 6-gingerol and 6-shogaol, allows identification 
of the shogaols family, as consequence of the appearance of the unsaturated bond. Thus, 
reading at 230 nm on HPLC-UV allows identification of the shogaols family. 
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1.3.2. Biological Activities of Ginger Rhizome 
Due to its abundance, low cost and safety in consumption, ginger has been the subject 
of intense scientific research over the past two decades. With scientific developments, ginger 
and specifically its compounds have shown anticancer, antibacterial, antifungal, 
hypoglycemic and antiatherosclerotic features. 
The consumption of ginger by those who are not accustomed to it may cause some 
temporary malaise, due to the spicy flavour, but there is no known acute toxicity in the doses 
of regular consumption, both in food and for medicinal purposes. On the other hand, very 
high doses (from 6 g) can lead to gastric irritation and loss of protective gastric mucosa. 
When administered, ginger was well tolerated up to a dose of 2.5 g/kg, with no mortality or 
side effects – except for diarrhea in two animals198. At doses of 3.0 g/kg and 3.5 g/kg, deaths 
(20 – 30%) and other secondary symptoms such as gastrointestinal spasm, hypothermia, 
diarrhea and anorexia occurred (30 – 60%). 
One case of contact dermatitis was reported related to ginger199. Ginger is on the 
FDA's GRAS list and its essential oils, oleoresins (solvent-free) and natural extractives 
(including distillates) are generally recognized as safe for their intended use, within the 
meaning of section 409 of the act200. 6-Gingerol is not considered cytotoxic, as it showed no 
effect on the viability of 3T3-L1 pre-adipocyte cell cytotoxic when tested in a concentration 
range of 1 ng/mL at 100 μg/mL for 24 h201. 
 
1.3.2.1. Gastrointestinal and Hepatic Activity 
Ginger, and the various extracts obtainable therefrom, have activity on the 
gastrointestinal tract. In the mouth, ginger stimulates the production of saliva, which enables 
swallowing. The digestion mechanism in the remaining gastrointestinal tract has been 
understood using animal systems202. It stimulates bile acid production and secretion and the 
activity of digestive enzymes of pancreas-lipase, amylase and proteases – namely, trypsin, 
chymotrypsin and carboxy peptidase203. In the small intestine, digestive enzymes also benefit 
from a diet with ginger204. Table 9 shows the data collected from the three tests mentioned, 
referring to the digestive enzymes activity in vivo studies in rats. 
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Table 9 – Summary table of results for pancreatic and intestinal enzyme activity in vivo studies with rats. 
Enzymes 
Effect204 
Dietary 
Effect203 Effect205 
Dietary Dietary Singular 
P
a
n
cr
e
a
ti
c Lipase  +
* –* +* 
Amylase  +* –* +* 
Trypsin  +* – +* 
Chymotrypsin  +* – +* 
In
te
st
in
a
l 
Lipase +*  +* +* 
Amylase ~  +* +* 
Alkaline phosphatase +  +  
Acid phosphatase +*  –  
Sucrase +  +* – 
Lactase –  + +* 
Maltase +*  – +* 
Note: 
+ – value superior to control, –  – value inferior to control, ~ – value equal to control, 
* – value statistically different from control. 
 
The continuous consumption of ginger for eight weeks led to the increase of the 
activity of the four pancreatic enzymes mentioned in the table203,205. On the other hand, the 
unique consumption of ginger leads to the decrease of the activity for all the pancreatic 
enzymes referred203. Thus, continued supplementation with ginger leads to an increase in 
pancreatic enzymes manifested by facilitated digestion and decreased intestinal transit time. 
There is an increase in the activity of intestinal lipase, whether it was continuous 
supplementation or daily intake. The intestinal amylase activity increased with ginger 
supplementation205, but this increase was not revealed in the previous study204. As the 
experimental supplementation conditions were not the same, there is no comparison of data 
between studies. 
Phosphatase activity was only statistically significant for acid phosphatase even 
though alkaline phosphatase activity also increased204. In the case of disaccharide enzymes, 
there is a variety of results for sucrase and lactase, leading to the question of whether the 
feed previously performed will or not also influence this enzymes activity204,205. Intestinal 
maltose was the only disaccharide enzyme that activity increased with ginger dietary 
supplementation. The intestinal peptidic enzymes undergo changes with a diet supplemented 
with ginger. Consumption of ginger leads to increased activity of glycyl-glycine dipeptidase, 
leucine amino peptidase and γ-glutamyl transpeptidase206. 
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Prakash and Srinivasan analysed the effects of ginger in the gastrointestinal tract in 
relation to the protective effect on the mucosa and the change in permeability. After ginger 
supplementation (0.05%) for eight weeks, there was a change in fluidity and permeability of 
the intestinal membrane, associated with increased length and perimeter of microvilli, 
resulting in an increase in the absorptive surface of the small intestine of rats206. With this 
same ginger supplementation for eight weeks, in an in vitro test, it was found that it lead to 
a greater absorption of iron, zinc, calcium and β-carotene207. Thus, dietary ginger exerts a 
beneficial influence on the gastrointestinal tract both in the enlargement of the contact 
surface for absorption, as well as the increase of the absorption rate, facilitating the intake 
of micronutrients. 
An ethanolic ginger extract (500 mg/kg) was shown to protect against ulcer formation 
by action of ethanol (80%), HCl (0.6 M), NaOH (0.2 M), NaCl (25%), indomethacin (30 
mg/kg body weight) and aspirin (200 mg/kg body weight) when administered to rats 30 
minutes prior to induction of the gastric lesion; no protective effect was observed on 
reserpine-induced gastric mucosal injury208. However, the composition of this extract was 
not ascertained. In another study, 6-gingerol (0.09%), was shown to reduce whatever-
induced stomach injuries by 34.8% when administered at a dose of 50 mg/kg and by 54.5% 
for a dose of 100 mg/kg192.  
In addition to the lesions induced with necrotic agents, these can also be induced by 
nonsteroidal anti-inflammatory drugs, such as indomethacin, aspirin and reserpine208. 
Supplementation with 500 mg/kg ethanolic extract of ginger (unknown composition) prior 
to administration of the inducing drug led to a decrease in gastric mucosal injury in the case 
of indomethacin and aspirin-induced injuries, but had no effect in reserpine-induced injury. 
The consumption of ginger is typically associated with an antiemetic activity209, even 
though there is no corroborating data. Furthermore, treatments with ginger did not reduce 
the incidence of nausea and vomiting in post-operative situations210,211. 
 
1.3.2.2. Antimicrobial Activity: Antibacterial and Antifungal 
Ginger and its extracts are given credit for antimicrobial activity, which may be 
important if ginger is used as a natural additive. Analysis of two literature studies claiming 
this has, however, shown the extracts were obtained by subcritical extraction with water212 
and ethanol198 and their composition was not assessed. Given the low solubility of gingerols 
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in these solvents, the extracts most likely do not contain these actives. Furthermore, the 
ginger extract has higher MICs when compared to the control, so the amounts needed to 
have an effective inhibition would be very high (between 80 and 160 times more)212. Thereby 
it is not possible to corroborate the antimicrobial activity of ginger and its components. 
 
1.3.2.3. Anti-inflammatory Activity 
Inflammatory activity results from the action of the enzyme cyclooxygenase (COX) 
or the synthesis of inflammatory prostaglandins. The use of non-steroidal anti-inflammatory 
drugs (NSAIDs) reduces inflammation, by enzymatic inhibition or synthesis. 
Various assays are carried out aiming to inhibit the enzyme, to lead to a decrease in 
the expression of a particular inflammatory compound or to observe the physical changes 
carried out by an inflammation. The enzymes and substrates associated with inflammatory 
activity – PGE2, PG synthetase and 5-LOX –, both in vitro and in vivo, and the development 
of edema were studied. Table 10 summarizes the information regarding the anti-
inflammatory activity in ginger powder rhizome and gingerols, considering the various types 
of tests performed and the conclusions achieved. 
 
Table 10 – Summary table of anti-inflammatory activity of ginger powder rhizome and gingerols. 
 Activity Dose  Effect Ref 
Ginger Reduction of PGE2 serum in vivo Orally 50 mg/kg 
Intraperitoneally 500 mg/kg 
213 
Carrageenan-induced edema reduction 50 mg/kg  22 % 
100 mg/kg  33% 
198 
Gingerols PG synthetase inhibition in vitro EC50 = 4.6 μM 6-gingerol 
EC50 = 5.0 μM 8-gingerol 
EC50 = 2.5 μM 10-gingerol 
214 
Reduction of PGE2 production in vitro 58% 6-gingerol 
66% 8-gingerol 
73% 10-gingerol 
215 
5-LOX inhibition in vitro EC50 = 30 μM 6-gingerol 
EC50 = 0.36 μM 8-gingerol 
EC50 = 0.053 μM 10-gingerol 
214 
 
It is necessary to mention that a bibliographical research about carragenan-induced 
edema with 6-gingerol done216, but after some analyze, it was found that there was no 
compliance between the concentrations of 6-gingerol referenced in the text with the 
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information in the chart, added to an incorrect interpretation of a significant decrease in 
edema. However, since the carrageenan-induced edema test is a test of anti-inflammatory 
activity and a validated one, it was considered important to make a brief reference217,218. 
Ginger has also been claimed to have anti-thrombotic features, since TXB2 levels 
were significantly decrease from oral administration of 500 mg/kg in rats213. Additional, 
antipyretic activity is considered as supplementation of rats for four hours with 100 mg/kg 
ginger ethanolic extract was found to reduce body temperature by 38% while the same dose 
of acetylsalicylic acid was effective in 44%198. Thus, the administration of ginger may act as 
an anti-inflammatory and it is a clinically important development since its administration 
does not cause side effects nor complications with non-steroidal anti-inflammatory drugs. 
 
1.3.2.4. Antioxidant Activity 
In order to analyze the effects of ginger as a dietary supplement for 
malathion-induced lipid peroxidation occurs, 1% (w/w) of ginger powder was added to 
standard laboratory diet and a feed containing malathion (20 mg of malathion in 1 kg of 
standard feed) was also prepared219. It was tested lipid peroxidation by TBARS, superoxide 
dismutase (SOD) and catalase (CAT) activity and the glutathione related enzymes: total 
glutathione (GSH), glutathione reductase (GR), by analysis the oxidation of NADPH to 
NADP, glutathione peroxidase (GPx) and serum glutathione S-transferase (GST) in blood 
samples. The results are reported in Table 11. 
 
Table 11 – Summary table of tests results carried out in antioxidant activity enzymes. 
 Ginger Malathion Malathion+Ginger 
Lipid peroxidation – a + ab – c 
SOD activity – + ab + abc* 
CAT activity – a + ab ~ bc 
GSH content + a – ab + c 
GR activity – + ab ~ c 
GPx activity – + ab – c 
GST activity – + ab + bc 
Note: 
+ – value superior to control, –  – value inferior to control, ~ – value equal to control, 
a – different from control, b – different from ginger, c – different from malathion, * – inferior to malathion. 
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The activity of malathion seems to be contraire to ginger and the malathion-diet 
supplemented with ginger. The results of this study suggest that ginger exerted an 
antioxidant effect, reducing lipid peroxidation, increasing GSH content and maintaining 
normal levels of antioxidant enzymes. High levels of antioxidant enzymes can be correlated 
with increased lipid peroxidation in the case of malathion feeding. Ginger leads to an indirect 
increase in GSH levels, increasing the amount of GTS. Analysis of the various glutathione-
related enzymes shows that GPx activity is correlated with GR activity, which provides 
substrate to the GPx enzyme, leading to an increase in the activity of the other enzymes as 
well. 
Several in vitro assays evidence the antioxidant activity of gingerols and 6-shogaol, 
as it can be noticed in Table 12. 
 
Table 12 – Summary table of antioxidant activity of gingerols and 6-shogaol. 
Assay Values Ref 
Free Radical Scavenging EC50 = 4.05 μM 6-gingerol 
EC50 = 2.50 μM 8-gingerol 
EC50 = 1.68 μM 10-gingerol 
EC50 = 0.85 μM 6-shogaol 
215 
Hydroxyl Radicals Produced by 
Fe(II)-H2O2 
EC50 = 4.61 μM 6-gingerol 
EC50 = 1.97 μM 8-gingerol 
EC50 = 1.35 μM 10-gingerol 
EC50 = 0.71 μM 6-shogaol 
215 
DPPH steady state at 180 min 20 μM 6-gingerol 220 
 
on DMSO 30 min at 37 °C 
6-shogaol > 10-gingerol > 8-gingerol > 6-gingerol 
EC50 = 26.3 ± 1.42 μM 6-gingerol 
EC50 = 8.05 ± 1.02 μM 6-shogaol 
215 
β-Carotene Bleaching  BHT=VE > 6-gingerol > MD-R=SFE-O > MD-EO 221 
Note: 
BHT – butylated hydroxytoluene; VE – vitamin E; MD-R – molecular distillation residue; 
SFE-O – supercritical fluid extracted oleoresin; MD-EO – molecular distillation of the essential oil. 
 
It is found that there is a vast analysis of the antioxidant activity of ginger and 
gingerols. As there is some variation between values related to the same assay, it can be seen 
that the specification of the composition and the solvent used influence the data. Therefore, 
the comparison with the laboratory data should take this into account. It is also needed to 
mention that the presence of the unsaturated bond in 6-shogaol may possibly lead to a higher 
antioxidant power and the length of the carbon chain also has an influence on the activity. 
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1.3.2.5. Hypoglycemic Properties 
Diabetes mellitus is one of the major metabolic disorders and a growing affliction in 
modern societies to which consumption of ginger may bring helpful health benefits. Ginger 
ethanolic extract with unknown composition showed hypoglycemic potential in rabbits. 
Doses of 100 and 300 mg/kg reduced glycemia by 46.1% and 51.4%, respectively, two hours 
following administration and the levels being maintained for another two hours198. 
In rats, results are also promising. A study involving diabetic hypercholesterolemic 
rats shown that supplementation with 3 g ginger for 30 days led to a significant reduction of 
blood glucose levels222. Another study with glucose intolerant diabetic rats with daily 
supplementation of 100 mg/kg of 6-gingerol for 12 days lead to a significant lowering of 
glucose levels after 90 minutes of glucose ingestion, which did not occur in untreated 
subjects201. Liver and renal (CAT, GPx and SOD) enzymes were also analyzed as well as 
malondialdehyde (MDA) concentration, by TBARS assay – data in Table 13. 
 
Table 13 – Impact of 6-gingerol (100 mg/kg) on hepactic and renal antioxidant enzymes (U/mg protein) and 
MDA concentration (mmol/L) in rats201. 
 Liver Kidney 
 db/+ db/db 6-gingerol db/+ db/db 6-gingerol 
CAT 10.5 ± 1.80 6.20 ± 2.50 ## 8.98 ± 2.40*** 8.5 ± 2.10 5.70 ± 2.50 ## 7.50 ± 2.40* 
GPx 65.4 ± 3.50 48.5 ± 2.90 ## 60.1 ± 2.70* 52.4 ± 3.50 38.5 ± 3.10 ## 47.0 ± 3.70** 
SOD 20.5 ± 2.50 14.2 ± 1.90 ## 18.2 ± 2.30** 23.0 ± 2.90 18.2 ± 2.30 # 21.3 ± 1.90* 
MDA 6.50 ±1.40 10.5 ± 1.50 ## 7.20 ± 1.80** 8.22 ± 1.80 12.6 ± 1.20 ## 9.60 ± 1.50* 
Note: 
db/+ – non diabetic; db/db – diabetic; 
in relation to db/+ (non diabetic) rats: # – p < 0.05, ## – p < 0.01, 
in relation to db/db (diabetic) rats: * – p < 0.05, ** – p < 0.01, *** – p < 0.001. 
 
In the liver of rats with diabetes the supplementation with 6-gingerol increased CAT 
(44.8%), GPx (23.9%) and SOD (28.1%) activity. An increased of kidney enzymes activity 
was also observed: CAT (24.0%), GPx (22.1%) and SOD (17.0%). It was observed that 
6-gingerol treatment conferred a significant reduction in lipid peroxidation in the liver 
(31.4%) and in the kidney (23.8%), when compared to diabetic rats. In diabetic rats, 
6-gingerol reduced the reactive oxygen spices content from 262.8% to 64.0%, after 12 days 
of treatment. The major outcome of this study is demonstrating that the supplementation 
with 6-gingerol allows the reduction of the activity of antioxidant enzymes, without causing 
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adverse effects to the individual. Supplementation with 6-gingerol also significantly reduced 
body weight from 50.4 ± 8.9 g on day 0 to 43.5 ± 7.8 g on day 12 in diabetic rats. 6-gingerol 
manifests ability to lower blood sugar, reduce body weight and change the production levels 
and plasma insulin concentrations. 
Ginger can inhibiting advanced glycation end products (AGEs) formation in vitro 
and in vivo, through its antiglycatory potential223. Blood glucose and insulin levels were 
evaluated to understand whether ginger improved the onset and progression of cataract, a 
pathological condition associated with the development of AGEs. With ginger 
supplementation, blood glucose levels declined to a low to moderate level, depending on the 
dose given to diabetic rats, while insulin levels were not affected. Thus, the delay in the 
progression of cataracts in diabetic rats due to ginger feeding may be attributed to their 
potential to modulate pathways. 
 
1.3.2.6. Cholesterol-lowering Properties 
Ginger is also being evaluated as a cholesterol regulating agent. There is a great 
concern with high levels of cholesterol, in particular concerning the role of low density 
lipoprotein cholesterol (LDL-C) it pathogenesis of atherosclerosis. 
The antihypercholesterolemic effects of ginger at various doses (Table 14) was 
evaluated in rats fed for previous 8 weeks with a high cholesterol feeding diet containing 1% 
cholesterol powder + 0.2% cholic acid + 10% fat224. 
 
Table 14 – Effect of oral administration of aqueous ginger infusion (100, 200 and 400 mg/kg) in serum 
triglycerides, total, LDL and HDL cholesterol224. 
 
Normal 
control 
Hypercholesterolaemic 
control 
Ginger 
100 mg/kg 
Ginger 
200 mg/kg 
Ginger 
400 mg/kg 
Triglycerides 10.32% ↓ 2.99% ↑ 42.53% ↓ 84.28% ↓ 90.49% ↓ 
Total cholesterol 0.45% ↓ 6.82% ↑ 70.85% ↓ 69.41% ↓ 77.96% ↓ 
LDL cholesterol 2.27% ↓ 2.81% ↑ 96.48% ↓ 97.86% ↓ 98.56% ↓ 
HDL cholesterol 2.33% ↑ 54.92% ↓ 29.83% ↑ 39.39% ↑ 29.86% ↑ 
 
Ginger infusion supplementation led to a reduction in serum triglyceride levels, total 
cholesterol and LDL cholesterol at all the tested doses, and in a dose-dependent manner for 
triglycerides and total cholesterol. On the other hand, the increase in ginger infusion 
supplementation did not lead to a more pronounced reduction of lipid LDL cholesterol. 
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Serum HLD cholesterol levels increased, having most notable increase for supplementation 
at 200 mg/kg. In parallel, a hypercholesterolaemic diet without supplementation led to an 
increase in triglycerides, total cholesterol and serum LDL cholesterol, and a decrease in HDL 
cholesterol. Ginger infusion at any of the concentrations led to a reduction in serum lipid 
levels. 
Seric cholesterol and triglycerides may also be associated with complication of 
diabetes. The effect of supplementation with 6-gingerol at 100 mg/kg for 12 days in diabetic 
rats showed a significant reduction in plasma triglyceride levels (41.1%), total cholesterol 
(31.2%), LDL (27.9%) and free fatty acids (24.4%)201. Comparing with the values presented 
in Table 14, where 100 mg/kg of an aqueous infusion of ginger was given, only the reduction 
of triglycerides was similar. It can thus be assumed that other components of the ginger 
rhizome and the time of supplementation influence the reduction of lipidic serum profile. 
Since high blood cholesterol is a risk factor for cardiovascular disorders, the 
hypocholesterolemic property of ginger should be indicative of its cardioprotective function. 
This was demonstrated using ginger ethanolic extract, that was able to prevent experimental 
isoproterenol-induced myocardial infarction225. This activity is related to the major active 
components of ginger, which comprise c.a. 51.7% of the extract composition (6-gingerol 
249.15 μg/mL, 8-gingerol 38.08 μg/mL, 10-gingerol 67.85 μg/mL, 6-shogaol 79.41 μg/mL, 
8-shogaol 12.24 μg/mL and 10-shogaol 34.81 μg/mL). Furthermore, pretreatment with 
ginger ethanolic extract 400 mg/kg for four weeks significantly decreased cardiac markers 
in rats – cardiac troponin I (cTnI), creatine kinase MB isoenzyme (CK-MB), lactate 
dehydrogenase (LDH), alanine transaminase (ALT) and aspartate transaminase (AST)225. 
Histopathologically, the control rats’ myocardium showed a normal morphological 
architecture with no evidence of necrosis, whereas in isoproterenol induced rats showed 
signs of necrosis, with infiltration of numerous inflammatory cells, as well as the separation 
of muscle fibers. Pretreatment with ginger extract at various concentrations showed 
decreased myocardial damage at 100 mg/kg and 200 mg/kg, while the myocardial structure 
with the pretreatment 400 mg/kg was almost comparable with the control group. 
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1.3.2.7. Cancer Preventive Properties 
The cancer-preventive activity of 6-gingerol is demonstrated by several in vitro and 
in vivo studies. Early reports used ginger and extracts of unknown composition, but, more 
recently, studies focused on the active compound 6-gingerol. In vitro, it is known that 
6-gingerol inhibited the viability of human HL-60 (promyelocytic leukemia) cells226 as well 
as the EFG-induced cell transformation and AP-1 activation in JB6 cells227, and nitric oxide 
synthase (NOS) expression in LPS-treated cell lines228, angiogenesis of human endothelial 
cells229 and AP-1 transcriptional complex in human skin keratinocytes cell lines230. 
In addition to the in vitro studies, in vivo studies were also conducted to evaluate 
ginger rhizome preventive character against cancer as well as other components per se. In in 
vivo studies in rats, 6-gingerol inhibited cell proliferation and induced apoptosis in colon 
cancer cells, not affecting normal cells (ERK1/2/JNK/AP-1 pathway inhibition)231. In skin 
related cancers, 6-gingerol supressed progression mouse skin carcinogenesis232 and inhibited 
TPA skin tumour promotion and epidermal ornithine decarboxylase activity in ICR mice226. 
It exhibited anti-tumour-promoting properties in topical application, by attenuated skin 
papillomagenesis233, and inhibited tumour growth and metastasis via anti-angiogenesis 
activity229. 
The previously reported laboratory and in vivo animal studies provide substantial 
evidence that 6-gingerol is an effective inhibitor of the carcinogenic process. Additional 
studies on the determination of anticancer activity should ideally include human intervention 
trials to investigate its efficacy against human cancers and other diseases. 
 
1.3.3. Other Applications of Ginger Rhizome 
In addition to the biological activities already referenced in the previous topics, there 
are several applications in the traditional medicine for ginger rhizome that science has tried 
to explain. Migraine is an event of a neurological nature that can be accompanied by visual, 
gastrointestinal and/or premenstrual disorders. Several hypotheses have been proposed to 
give the possible abortive effect of ginger on migraine headaches, focusing on the receptors 
already associated in migraine therapy. Agents in use for migraine therapy modify the 
release of transmitters in the transmission of pain, block the sensitization of nerve fibers or 
block the mechanisms of inflammation that surround the wall of blood vessels. Considering 
that ginger is used in the Ayurvedic and Tibb medicine systems, its consumption has been 
63 
 
proposed to respond to the pathology, verifying that there was a reduction in the incidence 
of migraines234. So, the consumption of fresh or powdered ginger may have an effect on 
migraine headache and its use may also be helpful in childhood and juvenile headache, as 
there are no side effects associated with this rhizome. 
6-gingerol was as well tested against the anti-writhing action. It was administered 10 
mg/kg indomethacin and 12.5 mg/kg, 25 mg/kg and 50 mg/kg of 6-gingerol to rats, in order 
to test the effect of 6-gingerol in writhing – twist the body about, in response to pain, in acute 
discomfort216. Both the administration of indomethacin and 6-gingerol (25 mg/kg and 50 
mg/kg) significantly reduced the number of writhing induced by 1% acetic acid for 10 
minutes. Thus, 6-gingerol may have an analgesic effect. 
 
1.3.4. Encapsulation of Ginger Compounds – State of the Art 
A search in SCOPUS scientific search engine on "cyclodextrin" and "gingerols" 
affords four hits. Two of these results are out of the scope of inclusion complex isolation, 
since the CDs are used to purify the ginger components in chromatography stationary phases. 
The third hit is a patent update about atherosclerosis, with reference to ginger as an 
antioxidant claim-mechanism235. The fourth result, an article from 2007 entitled 
“Preparation optimization and characterisation of ginger oleoresin/β-cyclodextrin inclusion 
complex”, has only the abstract available, allowing one to learn that the complexation 
process involved a mass ratio of β-CD:ginger oleoresin of 7:1 stirred for 1h at 65 ºC to afford 
an IC with a gingerol inclusion rate of 95%236. 
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1.4. Purpose of the Work 
Cyclodextrins are, as stated before, molecules that allow the encapsulation of various 
guests, affording a product with higher solubility and higher stability while the biological 
properties associated with the guest are maintained. In this work, we focus on two different 
types of guests be used, for the properties they present and for the interest in the scientific 
development of a regional product. 
Cistus ladanifer is a plant that develops only in the Mediterranean region, with 
antioxidant and antimicrobial properties, present at labdanum, flavonoid extract and 
essential oil. Specifically, Cistus ladanifer essential oil exhibits antimicrobial effects against 
bacterial and fungal strains, which are important for cosmetic and skin-safe products. Thus, 
research into the essential oil Cistus ladanifer may allow obtaining a product with 
antimicrobial activity, which may be important for application under bacterial conditions of 
the skin, such as acne, a microbial-associated condition that strikes immensely among young 
people. Thus, the application of the essential oil to a cosmetic product would be of interest 
and, in order to avoid the risk of skin irritation and/or rashes, the inclusion of the essential 
oil into cyclodextrins appears to be a good solution. Keeping in mind also that the 
encapsulation of Cistus ladanifer essential oil may not occur with all components of the 
essential oil, the selective inclusion of certain compounds may lead to the emergence of new 
interesting properties. 
Ginger also has a wide range of other properties. Although of Indian origin, it is 
widely distributed throughout the world, being used in traditional medicine with great 
appreciation. Considering the possible application of a ginger rhizome extract in the food, it 
is possible to emphasize the gastrointestinal, hypoglycemic and hypocholesterolemic 
activities, not excluding that it also has anti-inflammatory and antioxidant activity.  
Therefore, molecular encapsulation increases the application in matrices of a 
hydrophobic character different from those of the host molecule. 
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2. Experimental 
Next, it is presented the materials needed for the development of the work, as well as 
the protocols followed. With the protocols, the type of specific material required for the test 
is referenced. 
 
2.1. Materials 
Cistus ladanifer essential oil was acquired from Herdade de Vale Côvo, Mértola, 
Alentejo, an agrotourism and biological agriculture company. The extract containing 
gingerols was obtained from ginger rhizome acquired a local supermarket, as detailed in the 
subsection 2.2.5. below. 
β-Cyclodextrin decahydrate (β-CD, Mr = 1316 g/mol) and γ-cyclodextrin 
heptahydrate (γ-CD, Mr = 1440 g/mol), from Wacker-Chemie, were kindly offered by 
Ashland Specialty Chemicals. The gingerols standard (Mr=310.10 g/mol), dissolved in 
ethanol analytically pure, was provide from previous work. 
For the characterization methods and the biochemical assays, it was necessary 
potassium bromide (KBr) and acarbose solution, α-glucosidase enzyme solution, 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS), butylated hydroxyanisole 
(BHA), β-carotene, linoleic acid, 4-nitrophenyl-α-D-glucopyranoside solution, potassium 
persulfate (K2S2O8) and tween 80, all from Sigma-Aldrich. 
The following solvents (analytically pure) were used: acetone (from VWR), 
chloroform (Merck), deuterated chloroform (unknown brand), dichloromethane (unknown 
brand), dimethyl sulphoxide (VWR), ethanol (Panreão Química) and methanol (Fisher 
Scientific). 
For the production of yogurt, Mimosa® fat milk and Activia® yogurt (Danone®) were 
used. 
 
2.2. Methods 
 
2.2.1. Instrumentation 
The GC-MS analyses were performed on a CGMS (Gas Chromatograph Mass 
Spectrometer)-QP2010 Ultra equipped with autosampler AOC-20i, ion source of electronic 
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impact, an High-performance Quadrupole Mass Filter and a Agilent DB-5 ms column, with 
30 m length, 0.25 mm diameter and 0.25 µm thickness. The initial temperature of the oven 
was 50 °C and the temperature in the injector was 250 ºC. The injector went into split mode 
(1:50). The run was at 69.4 kPa, with a total flow of 65.0 mL/min and a column flow of 1.22 
mL/min. The linear velocity was 40.0 cm/s and the purge flow was 3.0 mL/min. The analysis 
proceeded at 50 ºC for 3 min, rising at 2 ºC per minute to 250 ºC, and maintained at that 
temperature for 10 minutes. The samples were dissolved in chloroform. 
Mass spectrometry (ESI-MS) was performed on a Micromass Q-TOF-2 ™ mass 
spectrometer. The ionization of the sample was done in electrospray in positive mode, with 
3 kilovolts in the needle and 30 volts in the cone. 
Fourier Transformed Infrared Spectroscopy (FT-IR) spectra were collected in a 
Mattson Unican Instrument. 7000 galaxy series FT-IR 7000 spectrophotometer using KBr 
pellets, averaging 64 scans at a resolution of 2 cm-1. According to this characterization 
method, the guests and the inclusion compounds were analyzed. For the guests, since there 
are two oily compounds, two extremely fine KBr pellets were made and the oil placed 
between the two. 
Differential Scanning Calorimetry (DSC) was carried out in a power-compensated 
DSC, PerkinElmer Diamond DSC. Following a five-minute lat period at 20 ºC, samples were 
heated to 270 °C at a rate of 5 °C/min. Sample mass was of 2.653 mg of ginger acetone 
extract and 3.616 mg for the respective inclusion complex. 
Liquid-fase 1H NMR and 13C NMR spectra were collected at 300 MHz using a Bruker 
Avance III. The samples were dissolved in deuterated chloroform in order to perform the 
assay, using tetramethylsilane (TMS) as standard. 
Solid State {1H} 13C CP/MAS NMR spectra were collected at 100.62 MHz on a 
Bruker AVANCE III 400 MHz (9.4 T) spectrometer, with a π/2 pulse, optimized at 3 
milliseconds Contact for 1H. Samples were run at 12 kHz with 4 seconds between scans. 
Powder X-Ray Diffraction (PXRD) data was collected at room temperature in a 
Philips X'Pert MPD diffractometer with a copper radiation Kα1 = 1.540598 Å, equipped 
with a X'Celerator detector and in a Bragg-Brentano configuration (40 kV, 50 mA). The data 
was collected in pulses of 0.04º and ¼ and ½ slits, continuously in 3.5º ≤ 2θ ≤ 50º interval. 
γ-CD·gingerols was also collected overnight with the following characteristics: pulses of 
0.02º and slits ⅛ and ¼, in a continuous 3.5º ≤ 2θ ≤ 50º interval. 
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Absorbance reading for the β-carotene, α-glucosidase inhibition and ABTS 
(2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) assays, were collected on 96-well 
plates with a EON BIOTEK plate reader, with Gen 2.05.5 software, using the specific 
working wavelength of each assay. 
The pH value of yogurts were measured with a glass electrode at 20 °C (pH electrode 
50 14, Crison Instruments, S.A., Spain) properly calibrated. 
The colour of manufactured yogurt was analyzed using a CM2300d spectrometer 
with Spectramagic NX software, both from KONICA MINOLTA. This portable 
spectrometer is specific for solid samples, so the assay for the yoghurt sample had to be 
slightly adapted. The samples were scattered on a watch glass and the equipment was placed 
on them. The portable spectrometer has a hole in which a sensor is located a few centimeters 
apart. The distance of the sample with the hole was taken into account so that the sample to 
be analyzed did not enter the hole. For the yogurt samples, the parameters L*, a* and b* were 
obtained (n = {5, 10}). 
 
2.2.2. Cistus ladanifer Essential Oil Physical Properties 
Density: The essential oil was characterized in relation to its density: 300 μL of essential oil 
was weighed, yielding a mass of 289.8 mg. Thus, the density is 0.966 g/mL. 
 
Molecular Weight: GC-MS analysis allowed to define a molecular mass for the essential oil, 
by analyzing the compounds which are in the composition of the essential oil and their 
amount. So, 10 μL of Cistus ladanifer essential oil was diluted in 1 mL of chloroform. The 
molecular weight of the essential oil is 143.685 g/mol with a 5.69% – this information will 
be developed in the subsection 3.1.1. 
 
FTIR (KBr):  (cm-1) = 3466 m, 2957 vs, 2923 vs, 2871 s, 2834 m, 2731 w, 2725 w, 
1790 sh, 1770 w, 1737 m, 1721 m, 1716 sh, 1713 sh, 1710 m, 1683 m, 1679 m, 1674 sh, 
1661 sh, 1652 w, 1645 w, 1634 w, 1626 w, 1617 sh, 1516 w, 1506 w, 1495 sh, 1467 sh, 
1463 sh, 1454 m, 1436 sh, 1418 w, 1411 w, 1383 m, 1375 m, 1365 m, 1336 w, 1328 w, 
1313 sh, 1306 sh, 1300 w, 1281 sh, 1261 sh, 1245 m, 1204 w, 1179 w, 1164 w, 1145 w, 
1125 w, 1112 w, 1100 sh, 1084 w, 1048 m, 1032 m, 1021 sh, 1014 sh, 997 sh, 953 w, 
945 sh, 926 sh, 887 m, 876 sh, 857 w, 843 sh, 839 w, 823 sh, 816 w, 801 sh, 787 w, 772 w, 
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760 w, 746 w, 737 vw, 725 sh, 720 w, 716 sh, 711 vw, 698 vw, 685 w, 668 w, 655 sh, 
649 w, 639 sh, 636 vw, 618 w, 611 w, 604 w, 597 sh, 591 w, 587 sh, 580 sh, 576 vw, 
564 w, 543 w, 537 sh, 531 sh, 525 w, 516 w, 511 vw, 482 vw, 478 vw, 472 vw, 467 sh, 
460 sh, 457 vw, 452 vw, 442 vw, 431 vw, 422 vw, 419 vw, 397 vw, 393 sh, 384 vw, 
374 vw, 359 sh, 350 w, 340 w, 334 w, 327 w, 323 w, 319 sh, 312 sh. 
 
2.2.3. Preparation of β-Cyclodextrin·Cistus ladanifer Essential Oil (β-CD·Cleo) 
The formation of the inclusion complex occurred by co-precipitation. Typically, to a 
saturated aqueous solution of β-CD at 40 °C237 (see Table 15) was added an equimolar 
amount of Cistus ladanifer essential oil dispersed in ethanol (1:3 proportion). 
 
Table 15 – Experimental conditions for each encapsulation reaction with β-cyclodextrin. 
Experiment β-CD (g) H2O (mL) Cleo (μL) Yield 
#1 0.5000 14.3 57 202.9 mg (36.4 %) 
#2 1.0014 28.7 113 296.2 mg (26.7 %) 
#3 2.0015 57.4 226 1 200 mg (54.1%) 
 
Each solution was allowed to cool slowly for one day and then placed in the 
refrigerator for two hours. Later, it was centrifuged at 3500 revolutions per minute (rmp) for 
30 minutes. The supernatant was withdrawn and the solutions stored in the refrigerator 
overnight. The solutions were then centrifuged again under the same conditions. The formed 
complexes were placed for four days in the presence of silica in order to withdraw the water 
still present in the sample. 
 
FTIR (KBr):  (cm-1) = 3349 vs, 2927 w, 2992 w, 2363 vw, 2358 vw, 2352 sh, 2341 vw, 
2338 sh, 2331 vw, 2324 sh, 2322 vw, 2307 sh, 1771 vw, 1748 sh, 1738 sh, 1732 vw, 
1716 sh, 1707 vw, 1700 w, 1695 vw, 1683 vw, 1652 vw, 1646 w, 1635 w, 1627 vw, 
1617 vw, 1576 vw, 1569 vw, 1558 vw, 1539 vw, 1532 vw, 1520 vw, 1516 vw, 1506 vw, 
1493 sh, 1488 sh, 1480 sh, 1456 w, 1446 w, 1436 w, 1430 w, 1423 sh, 1417 w, 1409 sh, 
1384 w, 1369 w, 1333 w, 1302 w, 1247 w, 1220 w, 1158 s, 1125 sh, 1112 sh, 1102 m, 
1080 s, 1057 s, 1029 vs, 1004 m, 945 w, 938 w, 905 vw, 888 vw, 861 vw, 840 sh, 758 w, 
703 w, 695 sh, 668 w, 652 w, 608 sh, 592 w, 575 w, 528 w, 502 w, 475 w, 443 w, 418 sh, 
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413 w, 398 sh, 357 w, 335 vw, 329 vw, 323 vw, 318 sh, 315 vw, 310 vw, 302 vw, 298 vw, 
295 vw, 290 vw, 286 vw. 
 
13C CP/MAS NMR (12 kHz, 25 °C, ppm): δ = 192.0, 180.0 (guest, C=O), 145.3, 128.3, 126.0 
(guest, aromatic region), 116.6, 110.7 (guest), 103.6, 102.8 (β-CD, C1), 83.8, 81.7, 80.7, 80.1 
(β-CD, C4), 74.3, 73.6, 72.6, 70.7 (β-CD, C2,3,5), 61.0, 60.0 (β-CD, C6), 50.6, 48.6, 46.6, 
41.3, 41.3, 37.1, 31.4, 27.4, 23.9, 21.1 (all guest). 
 
2.2.4. Preparation of γ-Cyclodextrin·Cistus ladanifer Essential Oil (γ-CD·Cleo) 
The encapsulation of C.ladanifer essential oil in γ-cyclodextrin followed the same 
procedure, taking into account that the solubility of γ-CD at 40 °C is 460 mg/g of water237. 
 
Table 16 – Experimental conditions for each encapsulation reaction with γ-cyclodextrin. 
Experiment γ-CD (g) H2O (mL) Cleo (μL) Yield 
#1 0.5000 1.1 52 245.1 mg (44.6 %) 
#2 1.0014 2.2 105 714.5 mg (71.3 %) 
#3 2.0015 4.4 210 1 786.9 mg (80.9%) 
 
The inclusion complexes were isolated following the procedure described in 2.2.3.  
 
FTIR (KBr):  (cm-1) = 3382 vs, 2926 w, 1734 w, 1772 sh, 1717 w, 1706 sh, 1700 w, 
1696 w, 1684 w, 1675 sh, 1670 sh, 1646 w, 1639 w, 1632 w, 1624 sh, 1618 w, 1458 w, 
1437 sh, 1416 w, 1405 sh, 1383 w, 1373 w, 1366 sh, 1337 w, 1303 w, 1246 w, 1201 w, 
1159 s, 1127 sh, 1106 m, 1080 s, 1058 sh, 1054 s, 1027 vs, 1002 s, 981 sh, 941 w, 865 w, 
839 sh, 815 sh, 794 sh, 761 w, 724 sh, 705 w, 686 w, 668 w, 660 w, 656 w, 651 w, 644 w, 
611 sh, 596 sh, 581 m, 565 sh, 531 w, 512 sh, 501 w, 496 w, 490 w, 479 w, 468 w, 463 sh, 
457 w, 448 sh, 443 w, 437 w, 432 w, 427 sh, 418 w, 411 w, 399 w, 391 sh, 384 w, 375 w, 
364 sh, 358 w, 351 w, 342 sh, 334 w, 328 w, 322 w, 319 sh, 311 w, 304 w, 300 sh, 296 w, 
290 sh. 
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13C CP/MAS NMR (12 kHz, 25 °C, ppm): δ = 191.3, 180.0 (guest C=O), 144.6, 129.3, 126.7 
(guest, aromatic region), 116.0, 110.0 (guest),105.2, 103.9 (γ-CD, C1), 82.6, 82.1, 80.8 
(γ-CD, C4), 74.3, 74.1, 73.6, 73.2, 72.8, 71.9, 71.2 (γ-CD, C2,3,5), 60.3 (γ-CD, C6), 50.6, 48.6, 
47.3, 41.3, 37.4, 31.4, 26.6, 23.9 (all guest). 
 
2.2.5. Evaluation of the Included Components 
In order to understand the encapsulation occurred, the hosts were extracted using 
chloroform, the cyclodextrin precipitated and the liquid was filtered, using nylon filters of 
0.45 μm porosity, so as to be injected into GC-MS for analysis. For this purpose, 101.2 mg 
of β-CD·Cistus ladanifer and 60.235 mg of γ-CD·Cistus ladanifer were precipitated with  
2 mL of chloroform, as use of chloroform allowed the release of the compounds that were 
encapsulated. These samples were analyzed by GC-MS, with the same characteristics 
referenced in subsection 2.2.2. 
 
2.2.6. Extraction and Purification of Ginger Extract from the Ginger Rhizome 
Chopped ginger (600 g) was extracted with acetone for 48 hours, under stirring on 
an orbital shaker at 90 rpm. The suspension was then filtered with gauze and the mother 
liquors were evaporated at reduced pressure. The oil was redissolved in water and extracted 
with mixtures of dichloromethane:methanol (3 x 100 mL), with growing polarities from 5% 
to 15%. After evaporation of the solvents the residue was redissolved with 50 mL of 
dichoromethane and rotavaped with 3 grams of silica gel until a solid residue was achieved. 
The silica column was prepared with dichloromethane and the powdered sample was added 
to the top of the column. At this point, elution with a solvent gradient, ranging from 1 to  
5 % methanol in dichloromethane and collection of a yellowish fraction gave rise to an 
impure fraction of ginger acetone. Further purification over preparative TLC plates (sample 
diluted with dichloromethane and eluted with chloroform) and evaporation of the solvents 
under reduced pressure provided 288.9 mg of pure ginger extract. 
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2.2.7. Ginger Extract Physical Characterization 
Mass Spectrometry: Mass spectrometry analysis allowed to define a molecular mass for the 
essential oil, by analyzing the compounds which are in the composition of the essential oil 
and their amount. The molecular weight of ginger extract is 314.71 g/mol. This information 
will be developed in the subsection 3.2.1.2.2. – Table 25. 
This sample contained other compound differing from 6-gingerol (Figure 9), as 
8- and 10-gingerol. In order to simplify the numerical assignment of the hydrogens and 
carbons as the assignment of all compounds differ from IUPAC identification, it was used 
letters instead of numbers, starting in the aromatic ring – this alteration made possible the 
identification of the carbonyl (Cj) and carbon identifying the gingerol (Cl) with the same 
letter. 
 
 
Figure 9 – Structure of 6-, 8- and 10-gingerol, with the letter identification used for this work. 
 
FTIR (KBr):  (cm-1) = 3461 vs, 2954 vs, 2951 vs, 2942 sh, 2937 sh, 2929 vs, 2926 sh,  
2921 sh, 2918 sh, 2884 s, 2876 sh, 2870 sh, 2857 s, 1736 w, 1707 s, 1704 s, 1698 s, 1693 s, 
1681 m, 1671 sh, 1665 w, 1659 w, 1649 w, 1643 sh, 1632 sh, 1619 sh, 1610 sh, 1602 m, 
1594 sh, 1573 w, 1556 w, 1562 w, 1555 sh, 1551 sh, 1547 w, 1515 vs, 1493 w, 1464 s, 
1453 s, 1439 sh, 1431 s, 1407 m, 1383 sh, 1375 sh, 1370 s, 1359 sh, 1271 vs, 1236 s, 
1208 s, 1187 sh, 1152 s, 1131 sh, 1123 s, 1087 m, 1034 s, 992 sh, 927 w, 894 w, 853 w, 
824 sh, 813 m, 796 m, 724 w, 706 w, 671 w, 665 sh, 624 w, 557 m. 
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1H NMR (20 ºC, ppm): δ = 6.84, 6.81 (H-f), 6.68, 6.65, 6.64 (H-a, H-b), 5.49 (c-OH), 4.02 
(l-OH), 3.87 (d-CH3), 2.96, 2.93 (H-l), 2.89, 2,87, 2.86, 2.84, 2,81, 2,76, 2.75, 2.73, 2.72, 
2.70 (i-CH2-h, g-CH2-a), 2.61, 2.60, 2.55, 2.52, 2.49, 2.46, 2.44 (k-CH2-j), 1.31, 1.28, 1.26 
(p-(CH2)n-m), 0.91, 0.89, 0.88, 0.86 (q-CH3). 
 
13C NMR (20 ºC, ppm): δ = 211.5 (Cj), 146.4 (Ce), 144.0 (Cc), 132.6 (Cg), 120.7 (Ca), 114.4 
(Cb), 111.0 (Cf), 67.7 (Cd), 55.9 (Cl), 49.3 (Ck), 45.4 (Ci), 36.4 (Cm), 31.7 (Ch), 29.3 (Co), 
25.1 (Cn), 22.6 (Cp), 14.0 (Cq). 
 
2.2.8. Preparation of γ-Cyclodextrin·Gingerols 
The formation of the inclusion complex, in which the host was the gingerols, 
proceeded in the same way as the formation of the referenced complexes. Starting with  
140.3 mg of gingerols for a stoichiometry of 1:1, 634.5 mg of γ-cyclodextrin was dissolved 
in 1.38 mL of water at 40 °C. Gingerols were diluted in 800 μL of ethanol and associated 
with the γ-CD solution. As the gingerols extract appeared to be more hydrophobic than 
Cistus ladanifer essential oil, the γ-CD·gingerols was left over night, about eighteen hours, 
at 40 °C in order to stabilize. Several aggregates of gingerols extract appeared, whereby  
1 mL of ethanol and 500 μL of methanol were added. This addition allowed to decrease the 
diameter of the gingerols extract aggregates. The final solution was allowed to cool slowly 
for four days. Then, the solution was centrifuged at 3500 rmp for 50 minutes and the 
supernatant was stored. The formed complex was placed in wristwatch glass overnight in 
the presence of silica. It was obtained 721.5 mg of complex, yield = 93.1 %. 
 
FTIR (KBr): (cm-1) = 3366 vs, 2946 sh, 2926 m, 2902 sh, 2851 sh, 1719 w, 1707 w, 
1703 w, 1698 m, 1693 m, 1687 sh, 1681 sh, 1677 w, 1672 w, 1664 sh, 1659 sh, 1657 w, 
1649 w, 1643 sh, 1632 w, 1625 sh, 1620 w, 1613 w, 1602 m, 1579 sh, 1572 w, 1565 w, 
1563 w, 1555 w, 1551 w, 1547 w, 1543 sh, 1535 sh, 1529 sh, 1524 sh, 1516 m, 1503 w, 
1492 sh, 1468 sh, 1460 w, 1453 w, 1431 sh, 1421 m, 1415 m, 1383 m, 1374 sh, 1351 sh, 
1336 m, 1300 w, 1273 m, 1255 w, 1240 m, 1200 w, 1158 s, 1126 sh, 1105 m, 1079 s, 
1051 sh, 1026 vs, 1001 s, 942 m, 935 sh, 917 sh, 890 w, 870 sh, 860 w, 810 sh, 793 sh, 
761 w, 704 m, 608 m, 580 m, 554 sh, 529 m, 476 w, 449 sh, 442 sh, 412 w, 400 sh, 390 w, 
362 w, 358 w, 346 w, 338 sh, 331 w. 
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13C CP/MAS NMR (12 kHz, 25 °C, ppm): δ = 210.0 (gingerols, Cj), 147.5 (gingerols, Ce), 
144.6 (gingerols, Cc), 132.5 (gingerols, Cg), 115.4 (gingerols, Cb), 111.7 (gingerols, Cf), 
105.2, 104.1 (γ-CD, C1), 82.9, 82.6, 82.3, 81.1 (γ-CD, C4), 74.6, 74.1, 73.7, 73.2, 73.0, 72.6, 
71.9, 71.2 (γ-CD, C2,3,5), 67.5 (gingerols, Cd), 60.8, 60.4 2 (γ-CD, C6), 56.7 (gingerols, Cl), 
50.0 (gingerols, Ck/i), 36.7 (gingerols, Cm), 31.7 (gingerols, Ch), 29.2 (gingerols, Co), 25.0 
(gingerols, Cn), 22.5 (gingerols, Cp), 14.2 (gingerols, Cq). 
 
2.2.9. Yogurt Manufacture 
Yogurt is a fermented dairy product widely consumed as functional food due to its 
good taste and nutritional properties, as it is rich in potassium, calcium, protein and vitamin 
B. Furthermore, it is an excellent vehicle to deliver probiotics to consumers238. It is the food 
produced by a characterised bacterial culture that contains the lactic acid-producing bacteria, 
Lactobacillus bulgaricus and Streptococcus thermophilus239.  
The yogurts were produced in laboratory, reproducing as similar as possible the 
conditions provided by a yoghurt maker. For this purpose, fat milk and yogurt were used, as 
the yoghurt provided the necessary bacterial culture to give the enzymatic changes for the 
yogurts production. Table 17 presents the quantities added in each flask in order to perform 
the assay. 
 
Table 17 – Conditions for yogurts production. 
  m compound added /mg m yogurt /mg v milk /mL 
Simple Yogurt 
#1 — 654.4 5.0 
#2 — 632.3 5.0 
#3 — 617.5 5.0 
Gingerols 
Yogurt 
#4 38.0 641.5 5.0 
#5 38.2 646.2 5.0 
#6 24.1 621.8 3.0 
γ-CD·Gingerols 
Yogurt 
#7 50.0 626.0 5.0 
#8 50.0 626.0 5.0 
#9 50.6 640.9 5.0 
Note: 
m compound added /mg – mass of gingerols/γ-CD·gingerois added to each vial in mg; 
m yogurt /mg – mass of yogurt added to each vial in mg; 
v milk /mL – volume of fat milk added to each vial, in mL. 
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The nine flasks were kept for 18 hours in a 40 °C bath, removed and stored in the 
refrigerator, similar to the conditions maintained during the production in a yoghurt maker. 
Note that although literature data often refers to the use of powder milk in yogurts 
formulations, a preliminary experiment in this work showed that this ingredient was 
unnecessary for the obtaining of a solid yogurt. 
 
2.2.10. Biochemical Assays 
The following tests were performed under gingerols and γ-CD·gingerols samples. 
For the ABTS assay, the gingerols and γ-CD·gingerols were previously applied in yogurts. 
The results and discussion are presented in subsection 3.4. 
 
2.2.10.1. β-Carotene Assay 
β-Carotene Solution and Blank Solution: First, a β-carotene solution (2 mg/mL) was 
prepared in chloroform. Next, a 1 mL of β-carotene solution was added to a round-bottom 
flask, where previously 1 g of tween 80 was weighed. Then, the chloroform was removed 
under reduced pressure and 40 ºC. Using the balance, it was added 50 mg of linoleic acid 
and the solution was homogenized. At last, a total of 100 g of water was slowly added to the 
previous mixture – the total removal of the chloroform from β-carotene solution led to a 
clean emulsion. It was also prepared a blank, which the 1 mL of β-carotene solution was 
replaced by 1 mL of chloroform. 
 
Standard Solution: A solution of BHA (0.5 mg/mL) was also prepared: about 10 mg BHA 
was weight and 1 mL of ethanol was added in order to dissolve the BHA. Then, the 
volumetric flask of 20 mL was completed with water. This solution was diluted to a 
2.5 µg/mL solution and seven standard solutions of BHA were prepared from this one – 
0.8 µg/mL, 1.0 µg/mL, 1.2 µg/mL, 1.4 µg/mL, 1.6 µg/mL, 1.8 µg/mL and 2.0 µg/mL. 
 
Samples Solution: For this assay, γ-cyclodextrin, gingerols extract and the encapsulation 
product were analyzed. The three samples solution were in the concentrations range of 
38.6 µM to 101.8 µM. Gingerols were previously dissolved in ethanol, since they are not 
soluble in water. 
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Method: 
On a 96-well plate, 40 μL of BHA or samples were applied, following by 200 μL of 
β-carotene or blank solution. The plates were incubated at 50 ºC for two hours and the 
absorbance was read at 470 nm. Values were compared with readings collected prior to 
incubation (baseline reading).  
The percentage of inhibition is calculated according to the equations below:  
∆ ABS c=0 = (ABS βc
c=0 − ABS Br
c=0)
0h
−  (ABS βc
c=0 − ABS Br
c=0)
2h
 − Equation 1 
∆ ABS c=? = (ABS βc
c=? − ABS Br
c=?)
0h
−  (ABS βc
c=? − ABS Br
c=?)
2h
 − Equation 2 
% of inhibition= 
∆ ABS c=0 − ∆ ABS c=?
∆ ABSc=0
×100 − Equation 3 
 
Table 18 explains the several abbreviations used in the equation. 
 
Table 18 – Resume table on the meaning of the abbreviation of the equations. 
Abbreviation Meaning 
ABS βc
c = 0 / ? Absorbance at concentration 0 or other concentration, with β-carotene and acid 
linoleic emulsion. 
ABS Br
c = 0 / ?
 Absorbance at concentration 0 or other concentration, with blank and acid linoleic 
emulsion. 
(ABS βc
c=0 − ABS Br
c=0)
0h
 Differential absorbance in the beginning of the assay. 
(ABS βc
c=0 − ABS Br
c=0)
2h
 Differential absorbance after 2 hours. 
 
2.2.10.2. α-Glucosidase Assay 
The α-glucosidase assay protocol was adapted from the existing protocol to rapidly 
understand the response of this enzyme to the sample. 4-nitrophenyl α-D-glucopyranoside 
was used as the substrate. This compound develops a yellow colour by hydrolysis, upon 
clivage. Acarbose, i.e. an anti-diabetic drug used to treat type 2 diabetes, was used as the 
reference inhibitor. 
A high concentration of gingerols – c = 1.03 x 10-3 mol/L, i.e., 0.325 mg/mL – was 
prepared in a solution of 40% DMSO and maintained frozen up to use. The 4-nitrophenyl 
α-D-glucopyranoside solution was diluted to 6 mM and the enzyme stock solution (1 U/mL) 
was diluted so that its activity was at 0.04 U/mL. 
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In a 96-well plate, it was added 50 μL of 40% DMSO solution, 50 μL of 4-nitrophenyl 
α-D-glucopyranoside solution and 100 μL alpha-glucosidase enzyme, in triplicate, and 
50 μL of 40% DMSO solution, 50 μL of 4-nitrophenyl α-D-glucopyranoside solution and 
100 μL of gingerols solution also in triplicate. The reaction kinetics were measured by 
measuring the absorbance at 405 nm, minute by minute, during 20 minutes. 
 
2.2.10.3. ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) Assay 
ABTS Solution: 38 mg of ABTS were dissolved in 10 mL of H2O and 6.6 mg of potassium 
persulfate (K2S2O8) was added. The solution was left in the dark for 12 hours and divided in 
aliquots. From one of this aliquots, it was retired 1 mL and diluted with 40 mL of 
ethanol:water 1:1, in order to the absorbance at 734 nm reached between 0.750-0.800. 
 
Standard Solution: A solution of ascorbic acid (1.42 mmol/L) was prepared: about 5 mg 
ascorbic acid was weight and dissolved in 20 mL of ethanol:water 1:1. Several dilution were 
prepared – 21.2 µM, 42.6 µM, 85.2 µM, 127.8 µM, 170.3 µM, 212.9 µM and 255.5 µM. 
 
Extracts Solutions and Dilutions: 
Extracts were obtained from the yogurts. To 
1 mL of ethanol was added to 1 g of yoghurt, 
and the sample was centrifuged for 
30 minutes at 3500 rpm. The supernatant was 
collected, whereby the extract was obtained. 
Dilutions were established for the extracts, 
using ethanol:water 1:1 – Table 19. 
 
Table 19 – Dilution applied for each sample. 
  Dilution factors 
Simple Yogurt 
#1 4, 16, 28, 40 
#2 4, 16, 28, 40 
#3 4, 16, 28, 40 
Gingerols 
Yogurt 
#4 16, 28, 40, 60 
#5 16, 28, 40, 60 
#6 16, 28, 40, 60 
γ-CD·Gingerols 
Yogurt 
#7 4, 16, 28, 40 
#8 4, 16, 28, 40 
#9 4, 16, 28, 40 
 
Method: 
40 μL of standard or sample and 200 μL of ABTS were added to each well (in 
triplicate). The microplate was left in the dark for 20 min and then the absorbance was read 
at 734 nm. Using only four dilutions of the samples, it is applied the standard solutions 
calibration line, in order to define the concentration in ascorbic acid equivalents. 
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3. Results 
As previously explored on Introduction section, cyclodextrin encapsulation of plant 
essential oils and lipophilic extracts is a good method to help stabilise their volatile 
components, protect light-sensitive compounds and increase their compatibility with 
aqueous formulations. For the encapsulation to be successful, the cyclodextrin must have a 
cavity adequate to the size of the molecules to encapsulate. 
 
3.1. Inclusion Complexes of Cistus ladanifer Essential Oil  
Prior to inclusion, the composition of Cistus ladanifer essential oil was investigated 
using GC-MS. Following, inclusion was attempted using two hosts: β- and γ-cyclodextrin, 
in order to understand if there is a selective encapsulation. The inclusion complexes were 
studied by infrared vibrational spectroscopy, solid state carbon 13 nuclear magnetic 
resonance ({1H} 13C CP-MAS NMR) and powder x-ray diffraction (PXRD). 
 
3.1.1. Cistus ladanifer Essential Oil GC-MS 
The GC-MS analyser is connected to a data base of compounds, listed in the program, 
GCMS Postrun Analysis, which allows assigning most of the peaks. For those with various 
matching compounds, assignment relied on a comparison with the different components of 
Cistus ladanifer essential oil described in the literature. The graphical representation of the 
GC-MS results for Cistus ladanifer essential oil is presented in the Appendix A. Results are 
presented in Table 20 and Appendix B. 
These two tables differed in the quantity of presented data. In Table 20, there are all 
the identified compounds with a percentage of area superior to 1%, while, in Appendix B 
table, there are all the compounds regardless the percentage of area. In this table, for the 
non-bibliographic identified compounds, the identification was established with similarity 
superior to 85% or, when this requirement was not obtained, it was tried to define the 
molecular weight. 
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Table 20 – Composition of Cleo. In this table, the majority components were selected, 
showing the retention time, compound name, molecular mass and peak area. 
Retention 
Time 
Compound Name % Area 
Molecular 
Weight 
7.439 Tricyclene 1.67 136 
7.947 α-Pinene 30.12 136 
8.667 Camphene 8.58 136 
8.872 Verbanene 0.94 134 
12.675 p-Cymene 4.44 134 
12.916 Limonene 1.93 136 
13.058 Eucalyptol 0.95 154 
13.293 2,2,6-Trimethylcyclohexanone 4.37 140 
14.685 δ-3-Carene 1.43 136 
19.060 α-Campholenal 1.67 152 
19.844 trans-Pinocarveol 5.77 152 
21.302 Pinocarvone 0.97 150 
21.939 Borneol 1.88 154 
22.171 Isopinocamphone 1.22 152 
22.522 4-Terpineol 1.15 154 
23.513 (-)-Myrtenal 0.80 150 
29.416 Bornyl acetate 8.31 196 
40.262 Aromandendrene 0.98 204 
48.270 Viridiflorol 2.70 222 
 
The average molecular weight (Mw) can be calculated by weighing the contribution 
of the components presented in Table 20, being thus estimated at 143.685 g/mol. Note that 
only 5.69% of the components remain unidentified and that these are not expected to 
significantly alter the Mw of Cistus ladanifer essential oil because they are most likely 
structural isomers with the same empirical formula (see table in Appendix B).  
 
3.1.2. Cyclodextrin·Cistus ladanifer Inclusion Complexes 
Cistus ladanifer inclusion complexes were prepared by co-precipitation, working 
close to the saturation for the host to favour the precipitation of the complex. Several 
experiments were conducted for each CD, as detailed in Tables 15 and 16 of the 
Experimental chapter. It is noteworthy that the yields for γ-CD·Cleo increased as larger 
quantities of the starting materials were used, but the same was not achieved in the case of 
β-CD·Cleo. 
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The complexes were characterized by Fourier transform infrared spectroscopy 
(FTIR), {1H} 13C CP/MAS NMR and powder X-ray diffraction. Information on the 
components of the essential oil that were included into the cavity of the CD was obtained 
from GC-MS, after the dissociation of an aliquot of the IC by selective dissolution of the 
guest into chloroform, in which the CDs are not soluble. Two cyclodextrins have different 
cavity size, meaning that β-CD may prefer to include components of smaller dimension 
while the γ-CD will include both smaller and larger components of the oil. The CG-MS 
analysis helps us understand selectivity associated with the process of encapsulation. 
 
3.1.3. Cistus ladanifer Encapsulated Compounds Analysed by GC-MS 
In order to examine the guest composition, the complexation process was reversed, 
precipitating cyclodextrin in chloroform, as described in subsection 2.2.5. It was possible to 
obtain a liquid which contained the guest composition and was analysed by GC-MS. In Table 
21, there is the identification performed by GCMS Postrun Analysis program and the defined 
composition of the essential oil. 
 
Table 21 – Composition of Cleo guest in β- and γ-CD complexes. Guest were analyzed by GC-MS 
and identification was made using the program and Cleo composition previously reported. For 
both complexes, it was possible to identify 76.38% of its composition. 
Retention 
Time 
Compound Name 
% Area of 
β-CD·Cleo guest 
% Area of 
γ-CD·Cleo guest 
7.947 α-Pinene 0.84 46.43 
8.667 Camphene  10.31 
12.675 p-Cymene  2.36 
13.293 2,2,6-Trimethylcyclohexanone  3.05 
19.844 trans-Pinocarveol  4.85 
29.416 Bornyl acetate 7.54 9.11 
30.201 Myrtenyl acetate 1.10  
35.112 Copaene 1.48  
37.765 Caryophyllene 0.81  
37.983 (+)-Aromadendrene 2.10  
40.262 Alloaromadendrene 5.67  
42.828 α-Muurolene 1.14  
44.009 δ-Cardinene 4.63  
46.865 (L)-Ledol 11.18  
47.508 Caryophyllene oxide 1.79  
48.846 Epiglobulol 38.1  
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The first observable difference between the GC-MS of pure and β-CD·encapsulated 
Cistus ladanifer essential oil is the almost complete absence of peaks in the retention time 
interval 4 to 30, while there are more components peaking within this interval in the case of 
γ-CD inclusion. Also noteworthy is a dramatic decrease in the number of peaks for both ICs, 
which is due to a selective inclusion, causing some compounds not to be included in the 
complexes. The different cavity size of the cyclodextrins allowed obtaining two ICs with 
different composition for the guest. Regardless of the cyclodextrin used, the essential oil 
composition is not maintained. β-CD encapsulated compounds of higher molecular weight 
and with high retention times, while γ-CD encapsulated compounds of lower molecular 
weight. The ICs are thus expected to have biological properties and activities different from 
those of the pure oil. 
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3.1.4. Fourier Transform Infrared Vibrational Spectroscopy Analysis (FT-IR) 
An IR can be interpreted as a fingerprint of the sample and it is also possible to have 
information on the molecular structure, since bonds have a spectrum zone in which they 
manifest. The spectra of β-CD·Cleo and γ-CD·Cleo (Figure 10, green and blue traces, 
respectively) feature a great similarity between both of them, due to the similar molecular 
structure of the cyclodextrins. So, the most informative bands are those ascribed to the 
contribution of the essential oil. The collected data for the guest alone (Figure 10, orange 
trace) as well as for the inclusion complexes should be analyzed by comparison in order to 
understand what differs between them. 
 
 
Figure 10 – FT-IR of Cistus ladanifer essential oil and its β- and γ-cyclodextrin inclusion complexes. 
 
Around 3466 cm-1, there is the contribution of the OH groups in the three samples240, 
even though the pure oil has a much lower band as expected. In the range of 2800 to  
2960 cm-1, the pure essential presents several peaks with relative intensities between medium 
and very strong, ascribed to asymmetric (CH) from CH2 and CH3 groups240. The complexes 
have only one broad band centered at 2927 cm-1 for β-CD·Cleo and 2926 cm-1 for 
γ-CD·Cleo. An expansion of the region between 800 and 1800 cm-1 is present in Figure 11. 
Table 22 shows a summary of the most relevant bands. 
 
84 
 
 
Figure 11 – Selected region of the spectra of Cistus ladanifer essential oil β-CD·Cleo and γ-CD·Cleo. 
 
Table 22 – Selected bands of pure Cistus ladanifer essential oil and its inclusion 
complexes. 
Cleo β-CD·Cleo γ-CD·Cleo 
Approximate 
Description240 
1738, 1716, 1710  1738, 1716, 1707  1734 ν(C=O) ester carbonyla 
1365 1369 1366 ωb(C-H) 
887 888  885 δ(C-O-C) 
Note: 
a – The observation of the C=O stretch in C. ladanifer oil is associated, according to 
Carrión-Prieto et al240, with the presence of triglycerides in the sample; 
b – ω is synonym of out of plane bending (wagging). 
 
The presence of bands around 1700 cm-1 is indicative of the presence of triglycerides 
in the essential oil, which were also included into the two hosts. These were not identified 
using GC-MS, since their molecular weight is too high when compared to the remaining 
compounds of the oil. It is to be further noted that the presence of these compounds in the 
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inclusion complex has no advantage, since these have no relevant biological activity and are 
competing with the active components of the oil for space inside the CDs 
 
3.1.5. Solid State {1H} 13C CP-MAS NMR  
The {1H} 13C CP-MAS NMR spectra β-CD, β-CD·Cleo, γ-CD and γ-CD·Cleo are 
depicted in the Figure 12. Green traces were used for β-CD samples and blue for γ-CD. For 
the inclusion complexes, lighter shades were used, leaving the darker ones for the 
cyclodextrin alone. 
 
 
Figure 12 – 13C {1H} CP/MAS NMR analisys of β- and γ-cyclodextrins and their inclusion complexes with 
Cistus ladanifer essential oil, with the assignments according to the literature241. 
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The most notable feature of the cyclodextrins and inclusion complexes is the 
modification of the multiplicity of the signals. While in the single cyclodextrins graphs, the 
signals were multiplied, for the same chemical shifts, in the graphs of the inclusion 
complexes, the signals are presented with lower multiplicity. In β-CD·Cleo, C2,3,5, C4 and 
C6 signals have double multiplicity, while carbons C1 appear as a single resonance. For 
γ-CD·Cleo, carbon 6 has simple multiplicity, whereas the remaining carbons present double 
or triple multiplicity. The change in multiplicity of the cyclodextrins’ signals is due to the 
channel structure and the presence of a guest inside of the inclusion complexes, which induce 
CDs to adopt a more symmetrical conformation. 
The spectra also present small resonances ascribed to the guest carbons. Given the 
complexity of the multicomponent sample and knowing that several compounds were 
included, it is possible to expect that the major compounds of each complex will be the 
contributors to the peaks identified. Thus, 13C NMR data of α-pinene, camphene, ledol and 
epiglobulol were used to proceed to an identification of the remaining signals – Table 23. 
 
Table 23 – Assignment of 13C RMN identified carbons with the major components identified by GC-MS, units 
in ppm. 
β-CD·Cleo γ-CD·Cleo α-Pinene242 Camphene243 Ledol244 245 246 Epiglobulol244 
192.0 191.3 possible tryglicerides not identified in GC-MS 
180.0 180.0 sppining sidebands from CDs influence 
145.3 144.6 144.51 (C1)    
128.3 129.3 n. i. 
126.0 126.7 n. i. 
116.0 116.0 116.14 (C2)    
110.7 110.0 n. i. 
50.6 50.6 n. i. 
48.6 48.6  48.3 (C4)   
46.6 47.3 47.24 (C3) 47.0 (C1)   
41.3 41.3  41.3 (C3) 40.9 (C5)+, 40.8 (C5)§ 42.9 (C9) 
37.4 37.4  37.4 (C7) 38.4 (C4)+*§, 37.8 (C9)* 37.6 (C5) 
31.4 31.4 
31.53 (C6) 
31.35 (C7) 
 
32.1 (C14)*, 30.6 (C14)+ 
30.5 (C14)§ 
31.2 (C14) 
27.4    28.7 (C12)+ (C13)§ 28.8 (C12), 27.1 (C7) 
 26.6 26.43 (C8) 25.9 (C10) 25.8 (C2)*, 25.1 (C7)+ 26.6 (C2) 
23.9 23.9  23.9 (C5) 23.5 (C6)+§  
21.1    22.3 (C6)*, 20.4 (C8)+ 20.6 (C11) 
Note:  + – Data from Bombarda et al.244, * – Data from Wu et al.245, § – Data from Kaplan et al.246; 
n. i. – not identified. 
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3.1.6. Powder X-Ray Diffractograms of Cistus ladanifer Inclusion Complexes 
Inclusion complexes were studied by powder X-rays diffraction, since the formed 
powders were microcrystalline. Figure 15 shows the diffractograms of β-CD (medium 
green), β-CD·Cleo (light green) and an illustrative diffractogram of a β-CD inclusion 
complex with the same organization pattern (dark green). 
 
 
Figure 13 – Powder X-ray diffratogram of β-CD (dark green), β-CD·Cleo (light green) and β-CD channel C2 
model, calculated from the atomic coordinates of bis(β-CD)·octanol clathrate pyrene247 with the software 
package Mercury® (darker green). 
 
Although the obtained pattern appears to be distinct, several similar peaks are 
present. However, some peaks of β-CD·Cleo are suppressed when compared to channel C2 
example. The absence of peaks of the sample in relation to the given example is not 
problematic and is justified by the fact that the sampling method in absorbance may lead to 
the suppression of some reflections. The difference in the pattern between the cyclodextrin 
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and the inclusion complex leads to the conclusion that there has been a restructuring of the 
host by the presence of a guest in the cavity. 
Figure 15 shows the diffractograms of γ-CD (dark blue), γ-CD·Cleo (light blue) and 
an illustrative diffractogram of a γ-CD inclusion complex with the same organization pattern 
(medium blue). 
 
 
Figure 14 – Experimental PXRD data of γ-CD (dark blue) and γ-CD·Cleo (light blue), and a simulated 
pattern for a model of γ-CD complex with channel packing. Data was from the single-crystal structure 
coordinates of γ-CD 18-crown-6 (medium blue)248, calculated using the software package Mercury®. 
 
γ-CD·Cleo has a pattern distinct from that of pure γ-CD, indicating that the sample 
is free from contamination with the crystalline host. Furthermore, the pattern has reflections 
at similar angles of two-theta as those typically observed for channel-packed inclusion 
complexes (see upper trace in Figure 14), but the reflections are broad and poorly resolved. 
Nevertheless, it is fair to assume that γ-CD·Cleo units are packing in the form of channels.   
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3.2. Inclusion Complexes of Gingerols 
This work was carried out as a follow-up to a bachelor’s degree project, in which the 
extraction of gingerols from fresh ginger rhizome using acetone maceration was optimized 
and the effect of cyclodextrins on the antioxidant and anti-inflammatory activities of 
solutions of gingerols was evaluated in vitro249. A new extraction of gingerols was carried 
out and the substance was analyzed for composition and molecular weight. The inclusion 
complex was then formed with γ-cyclodextrin and it was studied, using infrared vibrational 
spectroscopy, differential scanning calorimetry, {1H} 13C NMR CP/MAS and powder x-ray 
diffraction. 
Later, gingerols and γ-CD·gingerols were applied in yogurts and the physical 
characteristics of the fortified yoghurt were evaluated. The β-carotene and α-glucosidase 
assays were also performed the compound by themselves. The antioxidant activity of the 
manufactured yogurts was also study by ABTS˙+ assay. 
 
3.2.1. Extraction and Characterization of the Gingerols Extract 
 
3.2.1.1. Extraction 
The gingerols were obtained by maceration with acetone at room temperature, 
followed by chromatographic purification. Acetone is reported as the most effective solvent 
for the extraction of 6-gingerol from powdered dry ginger195. Note that other compounds of 
similar structure, 8- and 10-gingerols, share similar physico-chemical properties and 
therefore they are also present in the final product. 
 
3.2.1.2. Extract Analysis 
Gingerols extract was analysed by 1H NMR, mass spectrometry and infrared 
vibrational spectroscopy. For a comparison of the pure extract and its γ-CD inclusion 
complex, analyzes used {1H} 13C NMR (solution phase for the extract and solid-state for the 
complex) and DSC; the results of these techniques will be presented in the corresponding 
subchapters, below. 
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3.2.1.2.1. 1H NMR in Solution 
The 1H NMR spectrum of the extract, dissolved in CDCl3, is presented in Figure 15. 
Data was compared with that of the sample previously prepared by the bachelor student 
Bruna. The existing sample was denominated Fraction 1, and the gingerol extract herein 
prepared was denominated Fraction 2. Results are summarized in Table 24. 
 
 
Figure 15 – 1H NMR analysis of gingerols sample obtained by acetone extraction from ginger rhizome, also 
identified as Fraction 2. The peak at 5.30 ppm is referent to the used solvent. 
 
Figure 16 shows the structure of 6-gingerol, the major compound in both samples. 
Table 24 below shows the spectral data obtained for both samples as well as their integration. 
Each hydrogen was further identified with the literature221. The data obtained of 1H NMR for 
Fraction 1 is presented in Appendix C. 
 
 
Figure 16 – Structure of 6-gingerol. 
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Table 24 – Spectral data of the 1H NMR of 6-gingerol, Fraction 1 (previously obtained sample) and Fraction 
2 (sample obtained in the present work). 
 Literature221 Fraction 1 Fraction 2 
δ (ppm) Integration δ (ppm) Integration δ (ppm) Integration 
q-CH3 0.86 3.0341 0.86-0.91 3.13 0.86-0.91 3.07 
p-(CH2)n-m 1.25-1.59 8.4582 1.28-1.39 8.78 1.26-1.31 8.72 
k-CH2-j 2.44-2.59 2.0309 2.44-2.61 1.92 2.44-2.61 1.93 
i-CH2-h 2.70-2.76 1.9902 
2.70-2.87 4.01 2.70-2.89 3.98 
g-CH2-a 2.81-2.87 1.9823 
Hl 2.93 0.9519 2.94 0.65 2.93-2.96 0.88 
d-CH3 3.87 2.9818 3.87 3.05 3.87 3.07 
l-OH 4.05 1.000 4.02-4.04 1.03 4.02 0.93 
c-OH 5.50 0.9689 5.50 0.97 5.49 1.00 
H-a, H-b 6.64-6.71 1.9703 6.64-6.68 2.01 6.64-6.68 1.95 
H-f 6.78-6.84 0.9798 6.81-6.84 1.00 6.81-6.84 1.00 
 
Integrations match the expected values for all protons with the exception of 
p-(CH2)n-m which is slightly higher, denoting the contribution of 8- and 10-gingerols, that 
have more CH2 protons.  
 
3.2.1.2.2. Mass Spectrometry 
The extract was analyzed by TOF MS ES+, results presented in Figure 17. 
 
 
Figure 17 – Mass spectrum obtained for ginger rhizome extract in acetone. 
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The most intense peaks correspond to the monocations formed by gingerols with an 
adsorbed sodium. By subtraction of the sodium mass (Mr (Na+) = 22), it is known that  
m/z = 317.2 corresponds to 6-gingerol, m/z = 345.2 corresponds to 8-gingerol and  
m/z = 373.3 to 10-gingerol. Relative to the percentages obtained in the graph, where 100% 
corresponds to 6-gingerol and the percentages of 8-gingerol and 10-gingerol are 35% and 
47.5% respectively. This means that the extract has 54.05% of 6-gingerol, 19.45% of 
8-gingerol and 26.5 % of 10-gingerol, which implicates a molecular mass of 314.71 g/mol, 
as shown in Table 25. The sample will be called "gingerols" in the remaining subsections 
 
Table 25 – Ginger rhizome extract composition. 
m/z Compound Molecular Weight (g/mol) Quantity (%)  
317.2 6-gingerol 294.38 54.05 159.11 
345.2 8-gingerol 322.44 19.45 62.71 
373.3 10-gingerol 350.49 26.50 92.88 
Total Molecular Weight (g/mol) 314.71 
 
3.2.1.2.3. Fourier Transform Infrared Vibrational Spectroscopy Analysis (FT-IR) 
The spectra of the gingerols and γ-CD·gingerols are presented in the Figure 18. 
Gingerols are identified in orange and inclusion complex in blue. 
 
 
Figure 18 – FT-IR spectra of gingerol and γ-CD·gingerols. 
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Between 2800 and 3000 cm-1, the presence of several signals in the gingerols 
interferogram is observed, while in the inclusion complex are reflected in a signal of lower 
intensity and number of peaks – Table 26. 
 
Table 26 – Selected gingerol bands in the spectra of gingerols and γ-CD·gingerols. 
Gingerols γ-CD·Gingerols 6-Gingerol, description250 
1707 1707 1727, (C=O) 
1602 — 1652, (C=O) 
1515  1516  1517, (C=C) 
 
The corresponding bands were identified taking into account the contribution of 
γ-cyclodextrin, so that the area of great contribution of the CD was discarded. With the 
encapsulation, the intensity of the same peaks diminished, as well as some small deviation, 
in relation to the gingerols sample. 
 
3.2.2. γ-CD·Gingerols Inclusion Complex 
In a similar fashion to the inclusion complexes with Cistus ladanifer essential oil, 
inclusion of gingerols was performed by co-precipitation, working close to the saturation of 
γ-CD to favour the precipitation of the complex. The complex was characterized by Fourier 
transform infrared spectroscopy (FTIR), {1H} 13C CP-MAS NMR, differential scanning 
calorimetry (DSC) and powder X-ray diffraction.  
 
3.2.3. {1H} 13C CP-MAS NMR 
Gingerols and γ-CD·gingerols inclusion complex were analysed by {1H} 13C 
CP-MAS NMR. Gingerols analysed on its own allowed later to correlate with the data 
obtained for the inclusion complex sample. It is only stated that the gingerols sample was 
analysed in the liquid phase in deuterated chloroform and the inclusion complex was in the 
solid state. Figure 19 presents the {1H} 13C NMR spectra for gingerols (orange) and for both 
γ-CD (dark blue) and γ-CD·gingerols (light blue). 
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Figure 19 – {1H} 13C CP/MAS NMR analysis of gingerols (a), of γ-CD (b) and γ-CD·gingerol (c). 
γ-CD and γ-CD·gingerol have assignments according to the literature241. 
In γ-CD·gingerol, there are sppining sidebands from γ-CD influence (*) 
 
6-Gingerol peaks were identified by comparison with reported data 6-gingerol, as 
listed in Table 27. 
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Table 27 – Attribution of gingerol carbon resonances. 
 Literature221 Gingerols γ-CD·Gingerol 
Cq 13.9 14.0 13.9 
Cp 22.5 22.6 22.5 
Cn 24.9 25.1 25.0 
Co 29.1 29.3 29.5 
Ch 31.6 31.7 31.7 
Cm 36.3 36.4 36.7 
Ci 45.3 45.4 
50.0 
Ck 49.3 49.3 
Cl  55.9 56.7 
Cd  67.7 67.5 
Cf 110.9 111.0 111.7 
Cb 114.4 114.4 115.4 
Ca 120.6 120.7  
Cg 132.5 132.6 132.5 
Cc 143.9 144.0 144.6 
Ce 146.4 146.4 147.5 
Cj 211.3 211.5 210.0 
 
3.2.4. Differential Scanning Calorimetry (DSC) 
Gingerol and inclusion complex were analysed by differential scanning calorimetry 
(DSC). Results are presented in the Figures 20 and 21. 
 
 
Figure 20 – Differential scanning calorimetry analysis of gingerol. 
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The sample containing gingerols presents a phase change with the onset at 186.69 ºC 
and peaking at 210.07 ºC. The area is 389.575 mJ, with a ΔH of 146.8433 mJ/mg. 
 
 
Figure 21 – Differential scanning calorimetry analysis of γ-CD·gingerol. 
 
For the inclusion complex, three events can be observed in the DSC trace. The first 
two events, associated with the loss of hydration water molecules are observed with centres 
at 59.80 ºC, and 122.09 ºC. The loss of water molecules in two different steps is typical for 
CD inclusion complexes251 as some molecules are less tightly bound (usually these are 
clustered in spaces between the cyclodextrins), while other molecules, in stronger interaction 
with host or even guest molecules, are more tightly bound. Following, there is a third event 
centred at 233.18 ºC, with onset at 188.72 ºC and area of 133.363 mJ (ΔH of 36.8815 mJ/mg). 
This last transition can be associated with the endothermic peak of gingerols. Although it 
peaks at a slightly different temperature, possibly because of gingerols encapsulated in 
cyclodextrin, the onset occurs at the same temperature. 
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3.2.5. Powder X-Ray Diffractograms of Gingerols Extract Inclusion Complex 
The inclusion complex with gingerols as host was analyzed by powder x-ray 
diffraction. After a scan that took 10 minutes, the sample was analyzed overnight, with 
differentiation in the slits used, in order to increase the resolution – Figure 22. 
 
Figure 22 – Powder diffractograms of γ-CD.gingerols (bottom two) under different conditions and a 
simulated pattern for a model of γ-cyclodextrin complex with channel packing. Data was from the 
single-crystal structure coordinates of γ-CD 18-crown-6 (medium blue)248, calculated using the software 
package Mercury®. 
 
The trace collected in 10 minutes presents very low resolution, so the sample was re-
collected overnight, for higher signal intensity, and using narrow slits for noise 
minimization. The new diffractogram presents good resolution and adequate intensities for 
data modelling. The diffraction pattern presented in both data corresponds to the standard 
already defined for structures with cyclodextrins with guest organized in channel, and it can 
be postulated that the structure of γ-CD·gingerols is in channel. 
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Thus, through software, a Pawley’s fit was applied, using the atomic coordinates of 
known structure, γ-CD·18-crown-6-ether, it was possible to obtain the γ-CD·gingerols cell 
parameters – Figure 23. 
 
 
Figure 23 – Pawley’s fit on powder diffractograms of γ-CD.gingerols. 
 
In the noise line present in the upper figure, it is still possible to observe at low angles 
the presence of impurities. Nevertheless, it was possible to establish the parameters of the 
cell. The organization of γ-CD·gingerols cell is tetragonal, with a = b = 23.886(3) Å and 
c = 23.356(3) Å and α = β = γ = 90 º. 
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3.3. Yogurt with Gingerol 
By reproducing the homemade production of yogurt, yogurts fortified with pure or 
encapsulated gingerols were made in the laboratory using a thermostated water bath (details 
in the subsection 2.2.8). Figure 24 shows the resulting products. Vials identified from 1 to 3 
are plain yogurts, while the yogurts 4 to 6 and 7 to 9 correspond to yogurts fortified with 
gingerols and γ-CD·gingerols, respectively. Samples were made in triplicate for each 
fortification and masses were adjusted to have a fortification of 1% of gingerols or its 
equivalents (in the complexes) in each yogurt. Only sample 6 was prepared in a smaller 
amount, because the gingerols mass was not sufficient. 
 
 
Figure 24 – Photograph of yogurt produced in the laboratory – from left to right, the first three yogurts were 
not supplemented, the next three were fortified with gingerol, and to the last three was added γ-CD·gingerols. 
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3.3.1. pH variation 
The pH of the various samples was measured after one two and weeks of storage at 
4 ºC. Table 28 shows the pH values in two weeks. 
 
Table 28 – pH measurements on samples of simple and fortified yogurt with gingerois and γ-CD·gingerols. 
Sample 
Week 1 Week 2 Week 3 Week 4 
pH Odour pH Odour pH Odour pH Odour 
Simples 
Yogurt  
3.71 ± 0.06 — 3.73 ± 0.02 — 3.62 ± 0.04 + 3.59 ± 0.06 ++ 
Gingerols 
Yogurt 
3.72 ± 0.07 — 3.78 ± 0.06 — 3.65 ± 0.06 — 3.60 ± 0.04 — 
Complex 
Yogurt 
3.65 ± 0.06 — 3.71 ± 0.01 — 3.59 ± 0.04 — 3.56 ± 0.07 — 
 
The pH of the yogurts was measured during 4 weeks, with changes in values being 
found in the tenths of a unit. Regarding the odour, from the third week, there were 
organoleptic changes on the simple yogurts, being this still more active in the fourth week. 
 
3.3.2. Colorimetric Assay 
The equipment used allows to know the parameters L*, a* and b*. Figure 25 
demonstrates how color composition can occur with the variation of these three parameters. 
 
 
Figure 25 – Graphical interpretation of the parameters analysed: L* – black/white, +a*/–a* – red/green, 
+b*/–b* = blue/yellow252. 
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The nine samples of simple and fortified yogurt were evaluated for color to see if 
there was a difference between normal and fortified yogurt – data in Table 29. 
 
Table 29 – Colour parameters obtained for all samples and media (ȳ) obtained for the several parameters. 
Yogurt L* a* b* ȳ (L*) ȳ (a*) ȳ (b*) 
1 (n = 5) 88.980 – 1.408 3.500 
87.986 ± 5.003 – 1.317 ± 0.286 4.086 ± 1.053 2 (n = 5) 92.418 – 1.548 5.302 
3 (n = 5) 82.561 – 0.997 3.456 
4 (n = 10) 90.587 – 1.830 6.524 
89.076 ± 3.020 – 1.874± 0.155 6.646 ± 0.344 5 (n = 10) 91.044 – 2.048 7.035 
6 (n = 10) 85.598 – 1.746 6.380 
7 (n = 5) 83.964 – 1.372 3.678 
87.615 ± 5.258 – 1.620 ± 0.310 5.968 ± 2.066 8 (n = 5) 85.240 – 1.520 6.536 
9 (n = 5) 93.642 – 1.968 7.692 
 
With the values of ȳ (L*), ȳ (a*) and ȳ (b*), it is possible to calculate the associated 
error (ΔE) between the reference sample, i.e., plain yogurt, and the innovative samples. Thus, 
Equation 4 was applied, in which ΔL*, Δa* and Δb* is the difference in that parameter 
between reference sample and the gingerol and γ-CD·gingerols yogurt253. 
ΔE= √(ΔL*)2+ (Δa*)2+ (Δb*)2  − Equation 4 
 
Thus, for the gingerols yogurt, a ΔE = 2.84 was obtained, whereas for the 
γ-CD·gingerols yogurt, the ΔE decreased to 1.94. Note that the standard list defines that a 
ΔE between 0 and 1, the observer does not notice the difference; between 1 and 2, 
experienced observer can notice the difference; between 2 and 3.5, unexperienced and 
experienced observers notice the difference; between 3.5 and 5, it is noticed clear difference 
in colour; and, above 5, observers notice two different colours252.  
According to that, it would be possible to an unexperienced observer notice the 
difference between simple yogurt and gingerols yogurt, and it would be possible to an 
experienced observer can notice the difference between simple yogurt and γ-CD·gingerols 
yogurt. 
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The information obtained complements the 
observation made with the naked eye in the sample 
of gingerols yogurt, as it is possible to identify 
small droplets in yogurt. Figure 26 allows to 
observe the yellow droplets of gingerols in the 
yogurt. 
 
Figure 26 – Gingerol droples in yogurt. 
 
The presence of these droplets may influence the larger difference between plain 
yogurt and yogurt with gingerols, since during the collection of data the sample was not 
uniform. In addition, the equipment is specific for solid samples, which alone causes three 
errors. Firstly, the surface of the yogurt is not smooth, in which, during the data collection, 
the luminosity to which the sample is submitted differs, that is, the parameter L* has greater 
variation. Then the fact that the sensor is at a variable distance from the sample, since the 
sample can not touch the sensor, with the danger of spoiling it. Finally, and also related to 
the distance, the greater distances between the equipment and the sample there is a greater 
influence of the external luminosity. In order to reduce these sources of error, 5 or 10 
replicates were collected for each sample. 
It is possible, nevertheless, to associate the obtained parameters with the well-known 
RGB coordinates and to transform these into (x, y) coordinates, in order to apply them on a 
(x, y) Chromaticity Diagram. The conversion was obtained using two websites: from 
(L*, a*, b*) to (RGB)254, and in (x, y) coordinates255. The coordinates for each sample in the 
different colour models are presented in Table 30 and the (x, y) coordinates were applied in 
a CIE 1931 Chromaticity Diagram, defined in a (x, y) referential, presented in Figure 27. 
 
Table 30 – Table of coordinates conversion. 
 L*, a*, b* R, G, B Y, x, y 
Simple Yogurt 87.986, – 1.317, 4.086 221, 221, 213 72.572, 0.31813, 0.33796 
Gingerols Yogurt 89.076, – 1.874, 6.646 224, 225, 211 74.964, 0.32111, 0.34454 
γ-CD·gingerols Yogurt 87.615, – 1.620, 5.968 221, 220, 208 71.860, 0.32191, 0.34252 
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Figure 27 – Chromaticity diagram with the representation of simple and fortified yogurt samples. 
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3.4. Gingerols Biochemical Assays 
The antioxidant activity of gingerols, both pure and in the presence of CD, was 
evaluated in previous work by Bruna Pereira, using the by ABTS·+, 5-LOX inhibition and 
NO˙ scavenging assays249. Gingerols were shown to have a good antiradical activity towards 
ABTS·+, that was quite similar to that of the reference, Trolox. Gingerols also inhibited 
5-LOX, but their NO˙ scavenging ability was poor. Table 31 summarises the obtained 
results. 
 
Table 31 – Biochemical data from previous work with gingerols in the presence and absence of γ-CD249. 
 Biochemical Assay 
ABTS·+ 5-LOX NO·(% of inhibition) 
Standard Solution Trolox 
EC50 = 7,99±0,99 μM 
(2,00±0,25 μg/mL) 
Ascorbic acid 
EC50 = 234 ± 21 μM 
(0.0412 ± 3.7 μg/mL) 
Ascorbic acid (c = 1 mM) 
50.3 ± 1.9 %  
γ-CD — 42 % of inhibition (1000 μM) 11.3 ± 1.5% 
Gingerols EC50 = 9.13 ± 1.03 μM 
(2.83 ± 0.32 μg/mL) 
EC50 = 695 ± 47 μM 
(0.216 ± 0.015 mg/mL) 
17.5 ± 3.2 %  
γ-CD·gingerols EC50 = 8.80 ± 0.81 μM 
(2.73 ± 0.25 μg/mL) 
EC50 = 629 ± 101 μM 
(0.195 ± 0.031 mg/mL) 
25.3 ± 1.2 %  
 
3.4.1. β-Carotene Assay 
The antioxidant activity of gingerols, γ-CD and γ-CD·gingerols was further 
evaluated by the β-carotene assay, which uses this substrate in an emulsion with linoleic 
acid. This study allowed to evaluate the antioxidant activity of gingerols and γ-CD·gingerols, 
since oxidation of β-carotene by linoleic acid occurs in the absence of antioxidants. 
Results are represented in Figure 28. Note that γ-CD showed no antioxidant activity 
and therefore its percent inhibition graph is found in the Appendix E. The reference 
substance, BHA, used to evaluate the efficiency of the formulated emulsion thus verify the 
validity of this assay, is given in the Appendix D. 
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Figure 28 – Inhibition of β-carotene bleaching by gingerols and γ-CD·gingerols at different concentration. 
Data is represented as mean ± sd of three independent assays. Dashed lines represent the bleaching 
behaviour of the samples. 
 
The EC50 values for the two samples are very similar: EC50 = 83.3 ± 4.7 μM for 
gingerols and EC50 = 85.1 ± 7.1 μM for γ-CD·gingerols. EC50 values are not statistically 
significant, which means that the activity of the inclusion complex whose host is gingerols 
is equal to that of gingerols. Thus, cyclodextrin encapsulation does not alter the activity of 
this host, as it was observed in γ-CD’s antioxidant activity using this assay. 
 
3.4.2. α-Glucosidase Assay 
The α-glucosidase inhibition assay was first tested using a high concentration of 
gingerols (0.325 mg/mL, equivalent to 1.03 mM). At this concentration, gingerols displayed 
about 4.4 % inhibition, meaning that they are not good inhibitors of the α-glucosidase 
enzyme; no further studies thus were pursued regarding this system. 
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3.4.3. ABTS˙+ Assay in Yogurt Samples 
Further testing of antioxidant activity was performed by altering the matrix in which 
the compounds were included. In this assay, the dark green radical ABTS˙+ is generated by 
oxidation of ABTS with potassium persulfate (K2S2O8). The ABTS˙+ solution suffers 
decolorization in the presence of hydrogen-donating antioxidants. 
Test samples comprised a hydroethanolic extract of the yogurts. The use of 1 mL of 
ethanol had 3 objectives: first, since gingerols are hydrophobic, it assist in their incorporation 
into the extract; second, it increases the extraction power of the compounds under study; 
and, finally, it reproduce, as much as possible, the tested conditions used in the ABTS˙+ 
assay, made with ethanol:water 1:1 solutions. The design of the assay comprised defining 
the activity of the compounds in ascorbic acid equivalent, whereby the obtained graphic is 
in absorbance as a function of the concentration of ascorbic acid – Figure 30. 
 
 
Figure 29 – Ascorbic acid absorbance as a function of acid ascorbic concentration. Data is represented as 
mean ± sd of three independent assays. Dashed lines represent the expected behaviour ascorbic acid in other 
concentrations. 
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Table 32 – Test summary table: it presents the selected dilution factors, concentration of fortified 
compound in the dilution and the concentration related to ascorbic acid, extrapolated from Figure 29. 
Yogurt 
Dilution 
factor 
Concentration of gingerols or 
γ-CD·gingerols /μM 
Concentration from Figure 29 
/μM 
1 
4 
— 106.7 
2 — 101.4 
3 — 101.7 
4 
40 
302.50 211.9 
5 307.22 166.4 
6 330.32 148.2 
7 
28 
105.00 90.9 
8 103.66 135.4 
9 103.24 117.4 
 
Taking into account the dilutions and comparing with ascorbic acid, it can be defined 
that simple yogurt has a similar conduct to 0.826 ± 0.023 mM of ascorbic acid and, in 
fortified yogurts, gingerols yogurt has 14.041 ± 2.624 mM of ascorbic acid and 
γ-CD·gingerols yogurt has 6.416 ± 1.254 mM of ascorbic acid. 
As can be observed, gingerols-fortified yogurt showed the highest antioxidant 
capacity as compared to the remaining formulations. γ-CD·gingerols fortified yogurt also 
showed higher antioxidant capacity than that of the plain yogurt, thus indicating that the 
introduction of γ-CD·gingerols in complex matrix allow to improve their functionality. 
Note still that the antioxidant activity in γ-CD·gingerols yogurts was about half that 
of gingerols-fortified yogurt, even though the complex allowed to increase the solubility of 
these compounds. As previous ABTS˙+assay with gingerols and γ-CD·gingerols showed 
similar ABTS˙+ scavenging abilities249, the present results thus suggest that the antioxidant 
ability of γ-CD·gingerols in a complex milk matrix might be partially impaired in 
comparison to that observed in a simple solution.  
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4. Conclusion 
The main objective of the work, that is, to obtain and characterize inclusion 
complexes with multicomponent guests of plant origin, was successfully achieved. 
The composition of the guests was studied prior to inclusion. Cistus ladanifer 
essential oil (Cleo) was analysed by GC-MS, while gingerols extract was evaluated by MS 
and 1H NMR. Following inclusion, the process of preferential encapsulation was 
demonstrated for β-CD·Cleo and γ-CD·Cleo. Indeed, GC-MS analysis of the included 
material revealed a different composition than that of the guest, only a few of the components 
being included. The composition also varied according to the host employed, which was 
expected due to the slight difference in cavity size. 
These inclusion complexes would be applied in cosmetic products, specifically for 
young people with acne. As described in the introduction, the essential oil has antimicrobial 
properties. It would then be necessary to investigate whether encapsulation allowed to 
maintain this biological property. Using the inclusion complex, it would be possible to obtain 
a uniform and non-cloudy topical gel, a dermocosmetic product with the desired biological 
and visual properties. 
γ-CD·gingerols form a microcrystalline inclusion complex with a channel structural 
organization, as proved with PXRD. Fortified yogurts were made by the addition of 
gingerols and γ-CD·gingerols. The colour of the product changed slightly in regard to that 
of plain yoghurts, but this difference cannot be perceived by the average observer/consumer, 
only rather by an experienced observer. pH monitoring for two weeks did not show any 
changes, either for plain or fortified yoghurt (observation for a third week is going to 
establish if the gingerols are able to increase the shelf-life of the yoghurt). It is also noted 
that the dissolution of the gingerols into the milk matrix was not complete, so the formation 
of the inclusion complexes increased the solubility. 
Biochemical tests have also been carried out. The β-carotene assay showed no 
difference in the antioxidant activity of gingerols, either alone or in the form of inclusion 
complex. This result was corroborated by the absence of activity of γ-CD. The ABTS˙+ assay 
performed on yogurt extract, showed that gingerols retain their antioxidant activity. In this 
case, the differences between the action of gingerols and γ-CD·gingerols are more 
noticeable, in which the addition of 1% of compound is more effective in the case of 
gingerols.  
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Appendix A – Cistus ladanifer GC-MS Analyse (graphic figure) 
 
Figure 30 shows the GC-MS graph for Cistus ladanifer essential oil – 10 μL of 
essential oil in 1 mL of chloroform. 
 
 
Figure 30 – Graph of GC-MS obtained for the sample of Cistus ladanifer essential oil. 
 
 
 
132 
 
Appendix B – Cistus ladanifer GC-MS Analyse (table) 
 
Using the GCMS Postrun Analysis program, the following assignment was made – Table 33. The correspondence was confirmed by 
the bibliography. In some cases, only the molecular mass is presented, as where there was no concordance or similarity of less than 85% but 
which had the same molecular weight. 
The essential oil was defined as 143.685 g/mol molecular weight, with 5.69% unknown. 
 
Table 33 – Composition of Cistus ladanifer essential oil. 
Ret. Time Start TM End TM % Area % Height Compound Name Formula 
Mol 
Weight 
Bibliographic Similarity 
4.493 4.467 4.520 0.02 0.05 —    
5.013 4.955 5.052 0.12 0.21 —    
5.145 5.093 5.190 0.59 1.04 — C9H16 124  
5.861 5.810 5.917 0.10 0.11 —    
6.866 6.820 6.910 0.16 0.24 — C10H18 138  
7.339 7.302 7.370 0.04 0.06 (L)-Linalool C10H18O 154 
143,147,148 
7.439 7.377 7.508 1.67 2.25 Tricyclene C10H16 136 
138,141,144,146,256 
7.624 7.567 7.672 0.17 0.25 α-Thujene C10H16 136 
141,143,146,149,256 
7.825 7.770 7.858 0.49 0.68 — C8H16O 128  
7.947 7.860 8.042 30.12 35.44 α-Pinene C10H16 136 
131,138,141,143–149,256 
8.667 8.538 8.757 8.58 10.41 Camphene C10H16 136 
131,138,141,143–147,149,256 
8.872 8.807 8.942 0.94 1.18 Verbenene C10H14 134 
146,256 
8.997 8.953 9.042 0.08 0.14 —    
9.414 9.282 9.470 0.08 0.05 —    
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Ret. Time Start TM End TM % Area % Height Compound Name Formula 
Mol 
Weight 
Bibliographic Similarity 
9.602 9.550 9.665 0.11 0.14 — C8H14O 126  
9.820 9.763 9.918 0.21 0.31 Sabinene C10H16 136 
138,141,143,145,146,256 
10.028 9.953 10.125 0.55 0.63 β-Pinene C10H16 136 
141,143–145 
10.607 10.562 10.637 0.04 0.06 6-Methyl-5-hepten-2-one C8H14O 126  
10.717 10.662 10.818 0.22 0.19 Verbanol C10H16O 152 
130,149 
10.974 10.905 11.033 0.10 0.11 — C10H18O 154  
11.216 11.100 11.278 0.12 0.09 —    
11.546 11.478 11.677 0.38 0.25 —    
11.797 11.728 11.847 0.07 0.09 p-Cymenene C10H12 132 
131,141 
12.200 12.133 12.265 0.44 0.49 Terpinolene C10H16 136 
143 
12.408 12.372 12.448 0.02 0.03 —    
12.675 12.562 12.823 4.44 4.30 p-Cymene C10H14 134 
131,138,141,143–147,256 
12.916 12.837 13.003 1.93 1.68 Limonene C10H16 136 
131,143–145,147,256 
13.058 13.003 13.148 0.95 0.98 Eucalyptol C10H18O 154 
143,144,146,147,256 
13.293 13.200 13.402 4.37 4.45 2,2,6-Trimethylcyclohexanone C9H16O 140 
130,131,138,141,144,145,148,149,256 
14.185 14.027 14.273 0.47 0.27 — C10H20O 156  
14.421 14.387 14.470 0.03 0.04 —    
14.685 14.602 14.842 1.43 1.04 3-δ-Carene C10H16 136 
130 
15.007 14.955 15.070 0.04 0.04 — C10H18O 154  
15.227 15.143 15.358 0.12 0.08 —    
15.530 15.413 15.678 0.14 0.11 —    
15.990 15.920 16.053 0.17 0.17 — C10H18 or C9H14O 138  
16.227 16.177 16.280 0.12 0.12 —    
16.351 16.295 16.400 0.18 0.22 Terpinolene C10H16 136 
138,143,146 
16.501 16.447 16.573 0.15 0.13 Pinocarvone 
C10H14O or 
C11H18 
150 
131,141,145,149,256 
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Ret. Time Start TM End TM % Area % Height Compound Name Formula 
Mol 
Weight 
Bibliographic Similarity 
16.599 16.575 16.647 0.03 0.04 —    
16.727 16.653 16.825 0.76 0.71 —    
17.139 17.090 17.202 0.04 0.05 α-Pinene oxide C10H16O 152 
141,146 
17.337 17.267 17.573 0.39 0.17 ---    
17.844 17.755 17.967 0.56 0.38 —    
18.031 17.978 18.098 0.12 0.12 Rose oxide C10H18O 154 
141,144,147 
18.483 18.337 18.567 0.21 0.12 — C10H18O 154  
18.707 18.633 18.800 0.35 0.31 Verbenone C10H14O 150 
130,131,138,141,143–147,149 
18.874 18.828 18.935 0.04 0.04 —  154  
19.060 18.970 19.153 1.67 1.47 α-Campholenal C10H16O 152 
141,147,256 
19.212 19.167 19.308 0.13 0.11 Verbenol C10H16O 152 
130,149 
19.844 19.650 19.955 5.77 4.81 trans-Pinocarveol C10H16O 152 
131,145–147,256 
20.011 19.965 20.137 0.19 0.12 —    
20.257 20.172 20.360 0.74 0.61 (L)-(-)-Camphor C10H16O 152 
130,138,141,143,146,147,149 
20.583 20.498 20.660 0.23 0.21 —    
20.741 20.695 20.818 0.09 0.09 β-Linalool C10H18O 154 
143,147,148 
21.177 21.047 21.232 0.55 0.42 Isopinocamphone C10H16O 152 
143,145,147 
21.302 21.232 21.393 0.97 0.72 α-Pinocarvone C10H14O 150 
143,145,149 
21.441 21.393 21.527 0.30 0.26 —    
21.939 21.790 22.010 1.88 1.54 Borneol (same as Camphol) C10H18O 154 
130,131,138,141,143–149,256 
22.055 22.010 22.100 0.30 0.27 —    
22.171 22.100 22.308 1.22 1.02 trans-Pinanone C10H16O 152 
143,147 
22.522 22.385 22.623 1.15 0.99 4-Terpineol C10H18O 154 
138,141,145–147,256 
23.115 23.022 23.190 0.22 0.17 —    
23.513 23.415 23.560 0.80 0.68 (-)-Myrtenal C10H14O 150 
145,147,256 
23.597 23.560 23.710 0.59 0.53 Myrtenol C10H16O 152 
131,141,144–146,149,256 
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23.995 23.892 24.067 0.11 0.08 —    
24.337 24.262 24.420 0.29 0.26 Verbenone C10H14O 150 
130,131,138,141,143–147,149 
24.982 24.933 25.023 0.03 0.03 —    
25.118 25.060 25.163 0.04 0.04 —    
25.255 25.183 25.358 0.17 0.13 — C10H16O 152  
25.658 25.562 25.765 0.44 0.32 Isobornyl acetate C12H20O2 196 
138,141,143,146–148 
25.924 25.872 25.992 0.04 0.04 cis-Carveol C10H16O 152 
141,144,146,149 
26.449 26.302 26.550 0.79 0.50 — C10H18O 154  
26.866 26.797 26.973 0.11 0.09 — 
C10H14O or 
C11H18 
150 
 
27.238 27.212 27.283 0.02 0.02 trans-Pinocarveol C10H16O 152 
144,146,256 
27.475 27.377 27.568 0.52 0.42 —    
27.843 27.802 27.917 0.03 0.03 —    
29.416 29.285 29.585 8.31 6.74 Bornyl acetate C12H20O2 196 
138,141,143,146–149,256 
29.999 29.947 30.033 0.03 0.04 Isobornyl acetate C12H20O2 196 Bornyl acetate exclusion 
30.201 30.118 30.285 0.20 0.17 Myrtenyl acetate C12H18O2 194 
145–147 
30.730 30.690 30.802 0.04 0.04 —    
30.910 30.872 30.952 0.03 0.03 — C15H24O 220  
31.086 31.020 31.150 0.10 0.10 — C12H18O2 194  
31.995 31.917 32.093 0.45 0.37 trans-Pinocarvyl acetate C12H18O2 194 
Myrtenyl acetate 
exclusion 
32.188 32.115 32.270 0.14 0.12 —    
32.778 32.698 32.850 0.17 0.15 Carvyl acetate C12H18O2 194 
147 
33.356 33.290 33.432 0.11 0.10 α-Cubebene C15H24 204 
141 
34.608 34.433 34.718 0.92 0.56 (+)-Cyclosativene C15H24 204 
138,147 
35.112 35.020 35.212 0.64 0.51 α-Copaene C15H24 204 
141,145–147 
35.457 35.402 35.612 0.11 0.09 —    
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36.018 35.948 36.100 0.07 0.06 (+)-Sativen C15H24 204 Aromadendrene exclusion 
36.465 36.423 36.533 0.04 0.04 — C15H24O 220  
37.040 36.957 37.135 0.13 0.10 Patchoulene C15H24 204 
141 
37.765 37.683 37.833 0.14 0.12 Caryophyllene C15H24 204 
141,143 
37.983 37.937 38.037 0.02 0.02 (+)-Aromadendrene C15H24 204 
131,141,143,145–147,256 
39.060 39.002 39.115 0.03 0.03 — C15H24 204  
40.262 40.143 40.377 0.98 0.75 Alloaromadendrene C15H24 204 
131,141,143,145–147,256 
41.113 41.060 41.183 0.04 0.04 Epi-Cubebol C15H26O 222 
141,146,147 
41.341 41.282 41.413 0.10 0.09 — C15H24 204  
42.048 41.968 42.130 0.17 0.14 β-Eudesmene C15H24 204 
143,145 
42.248 42.177 42.348 0.31 0.24 Viridiflorene C15H24 204 
131,256 
42.515 42.453 42.603 0.04 0.04 —    
42.828 42.765 42.907 0.10 0.09 α-Muurolene C15H24 204 
141,145,146 
43.622 43.555 43.693 0.15 0.13 —    
44.009 43.925 44.095 0.46 0.35 δ-Cardinene C15H24 204 
131,138,141,145–147 
44.175 44.117 44.283 0.17 0.13 —  202  
45.273 45.222 45.328 0.04 0.04 α-Calacorene C15H20 200 
141,146,147 
46.865 46.790 46.932 0.11 0.09 (L)-Ledol C15H26O 222 
130,144,145,147,256 
47.308 47.250 47.367 0.06 0.05 Spathulenol C15H24O 220 
131,141,145,147,149,256 
47.508 47.432 47.603 0.14 0.11 Caryophyllene oxide C15H24O 220 
131,141,145,146,149 
48.270 48.143 48.472 2.70 1.65 Viridiflorol C15H26O 222 
131,138,141,144–147,149,256 
48.846 48.742 48.970 0.76 0.53 Epiglobulol C15H26O 222 
131,145,149 
49.148 49.053 49.243 0.14 0.09 Copaborneol C15H26O 222 
256 
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Appendix C – 1H NMR Analysis of Gingerols Extract – Fraction 1 
 
Figure 31 shows the 1H NMR graph of the gingerols for the existing sample. The 
data are also reported in Table 25, under the name of Fraction 1. 
 
 
Figure 31 – 1H NMR analysis of gingerols sample also identified as Fraction 1 
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Appendix D – β-Carotene Inhibition by Butylated Hydroxyanisole (BHA)  
 
For the development of the assay, there must be a substance whose response to 
β-carotene is known. Thus, butylated hydroxyanisole (BHA) is used by standard. This 
antioxidant consists of a mixture of two isomeric organic compounds: 
2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole. 
 
 
Figure 32 – Graphic of the inhibition of the BHA standard by the emulsion β-carotene and linoleic acid. 
Dashed lines represent the bleaching behaviour of BHA. 
 
As the concentration of BHA increases, the percentage of inhibition also increases. 
It is possible to obtain an EC50 for the BHA, this being 1.26 ± 0.18 μg/mL. 
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Appendix E – β-Carotene Inhibition by γ-CD  
 
Figure 33 shows the inhibition caused by γ-CD. 
 
 
Figure 33 – Graph of the inhibition of γ-cyclodextrin by the emulsion of β-carotene and linoleic acid. 
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Appendix F – ABTS˙+ Assay: Ascorbic Acid Inhibition Graphic 
 
The ascorbic acid’ absorbance data was applied in the following equation – Equation 
5 –, in order to obtain the percentage inhibition. 
% of inhibition= 
ABSc = 0 − ABSc = ?
ABSc = 0
×100 − Equation 5 
 
 
Figure 34 – Graph of the inhibition of ascorbic acid in ABTS˙+. 
 
As the concentration of ascorbic acid increases, the percentage of inhibition also 
increases. It is possible to obtain an EC50 for the acid ascorbic, this being 183.3 ± 14.9 μM. 
 
 
